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Abstract	  
Glioblastoma	  multiforme	  is	  the	  most	  common	  malignant	  primary	  intracranial	  tumor	  
in	  adults.	  Despite	  years	  of	  advances	  in	  basic	  science	  knowledge	  about	  this	  disease	  
including	  but	  not	  limited	  to	  cellular	  hierarchy,	  genetics,	  and	  mechanisms	  of	  
proliferation	  and	  spread,	  overall	  survival	  of	  patients	  has	  remained	  unmoved	  for	  the	  
past	  fifteen	  years,	  and	  long-­‐term	  survivors	  are	  nearly	  nonexistent.	  Barriers	  to	  
improved	  treatment	  occur	  in	  the	  realms	  of	  engineering	  and	  drug	  discovery:	  creation	  
of	  an	  efficient	  delivery	  vehicle	  and	  identification	  of	  novel,	  efficacious	  small	  molecule	  
compounds	  are	  necessary	  to	  achieve	  survival	  benefit	  in	  this	  disease.	  
In	  the	  following	  thesis,	  I	  describe	  efforts	  made	  by	  myself	  individually	  and	  alongside	  
members	  of	  the	  laboratory	  of	  W	  Mark	  Saltzman,	  PhD,	  Goizueta	  Foundation	  
Professor	  and	  Chairman	  of	  Biomedical	  Engineering,	  to	  test	  a	  novel,	  highly-­‐
penetrative	  polymeric	  nanocarrier	  platform	  for	  intracranial	  drug	  delivery	  and	  
develop	  a	  high-­‐throughput	  screen	  for	  small	  molecule	  compounds	  with	  efficacy	  
against	  brain	  cancer	  stem	  cells.	  I	  show	  that	  the	  combination	  of	  the	  efficient	  delivery	  
system	  and	  small	  molecule	  compounds	  with	  efficacy	  against	  brain	  cancer	  stem	  cells	  
produces	  unprecedented	  gains	  in	  survival	  in	  a	  rat	  model	  of	  glioblastoma.	  Further,	  I	  
describe	  the	  design	  and	  quality	  control	  methodology	  of	  the	  high-­‐throughput	  small	  
molecule	  screen	  and	  identify	  a	  large	  number	  of	  small	  molecule	  compounds	  with	  
equal	  efficacy	  to	  first-­‐generation	  anti-­‐brain	  cancer	  stem	  cell	  drugs	  with	  fewer	  safety	  
concerns.	  Together,	  the	  data	  underscore	  a)	  the	  promise	  of	  this	  efficient	  delivery	  
vehicle	  to	  rapidly	  test	  the	  identified	  anti-­‐brain	  cancer	  stem	  cell	  compounds	  and	  b)	  
the	  potential	  for	  this	  combination	  to	  revolutionize	  glioblastoma	  therapy.	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Introduction	  
Glioblastoma	  Multiforme:	  Epidemiology	  and	  Histology	  
Glioblastoma	  multiforme	  (more	  recently	  referred	  to	  as	  simply	  “glioblastoma”	  and,	  
herein,	  “GBM”)	  is	  the	  most	  common	  malignant	  primary	  intracranial	  tumor,	  with	  
approximately	  15,000	  new	  cases	  each	  year	  [1].	  The	  disease	  most	  commonly	  affects	  
older	  non-­‐Hispanic	  white	  male	  patients	  between	  the	  ages	  of	  30	  and	  60	  [2].	  Patients	  
most	  commonly	  present	  with	  headaches,	  development	  of	  seizure,	  and	  other	  
complications	  related	  to	  mass	  effect	  rather	  than	  tumor	  [3].	  GBM	  is	  suspected	  upon	  
magnetic	  resonance	  imaging	  (hereafter	  “MRI”)	  and	  is	  characterized	  by	  a	  deeply	  
located,	  large,	  contrast-­‐enhancing	  mass	  with	  central	  necrosis.	  The	  spatial	  
distribution	  of	  GBM	  is	  most	  frequently	  frontal	  (40%)	  and	  temporal	  (29%);	  when	  
accounting	  for	  brain	  volume	  this	  asymmetric	  distribution	  of	  origins	  remains	  
pronounced	  [4].	  Compared	  with	  low-­‐grade	  gliomas,	  which	  are	  frequently	  
peripheral,	  GBM	  is	  often	  found	  in	  deeper	  cortical	  locations,	  including	  the	  insula.	  
In	  contrast	  to	  metastatic	  tumors,	  World	  Health	  Organization	  classification	  of	  glial	  
tumors	  is	  grade-­‐only	  and	  is	  performed	  on	  a	  I-­‐IV	  basis	  ([5];	  Table	  1).	  Tumors	  of	  both	  
oligodendroglial	  (red	  print	  in	  Table	  1)	  and	  astrocytic	  (blue	  print	  in	  Table	  1)	  lineages	  
occur	  and	  are	  indistinguishable	  on	  MRI.	  Within	  the	  oligodendroglial	  lineage,	  it	  is	  not	  
at	  all	  uncommon	  for	  tumors	  to	  contain	  pockets	  of	  proliferative	  astrocytes.	  
Accordingly,	  these	  lesions	  are	  named	  as	  a	  portmanteau	  of	  cell	  types:	  
oligoastrocytoma.	  Only	  astrocytic	  lineage	  tumors	  have	  a	  grade	  I	  form;	  this	  lesion	  is	  
most	  frequently	  found	  supratentorially	  in	  pediatric	  populations	  and	  is	  referred	  to	  as	  
pilocytic	  astrocytoma	  for	  its	  hair-­‐like	  projections	  and	  well-­‐circumscribed	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architecture.	  Grade	  II	  lesions	  are	  generally	  referred	  to	  as	  the	  low-­‐grade	  gliomas.	  
Within	  the	  astrocytic	  lineage,	  the	  lesion	  of	  note	  is	  diffuse	  astrocytoma	  –	  essentially,	  
a	  pilocytic	  astrocytoma	  that	  has	  lost	  its	  well-­‐circumscribed	  tissue	  architecture	  but	  
does	  not	  contain	  overtly	  malignant	  cells.	  The	  oligodendroglial	  lineage	  is	  made	  up	  of	  
oligodendroglioma	  or	  oligoastrocytoma	  and	  are	  infiltrative	  masses	  dominated	  by	  
“fried	  egg”	  appearing	  oligodendroglial	  cells	  without	  mitoses.	  Grade	  III	  tumors	  
generally	  have	  anaplastic	  features	  such	  as	  mitoses	  and	  hyperchromasia;	  
accordingly,	  they	  receive	  the	  “anaplastic”	  descriptor.	  Whereas	  in	  the	  astrocytic	  
lineage	  these	  tumors	  have	  no	  tissue-­‐level	  malignant	  features	  like	  vascular	  
proliferation	  (or	  endothelial	  proliferation,	  terms	  used	  interchangeably)	  or	  central	  
necrosis,	  those	  in	  the	  oligodendroglial	  lineage	  are	  marked	  by	  vascular	  proliferation.	  
Finally,	  grade	  IV	  tumors,	  GBMs,	  have	  characteristic	  histologic	  findings	  of	  necrosis	  
and	  (or,	  in	  the	  case	  of	  astrocytic	  tumors)	  vascular	  proliferation.	  
There	  are	  thought	  to	  be	  two	  major	  pathways	  by	  which	  GBMs	  evolve,	  and	  are	  
referred	  to	  as	  either	  primary	  or	  secondary	  GBMs	  [6-­‐11].	  Primary	  GBMs	  occur	  de	  
novo	  typically	  in	  older	  patients	  and	  do	  not	  contain	  p53	  mutations,	  whereas	  
secondary	  GBMs	  occur	  in	  younger	  patients	  and	  are	  advanced	  tumors	  that	  have	  
evolved	  from	  a	  low-­‐grade	  glioma	  in	  situ	  and	  possess	  p53	  mutations	  and	  often	  
IDH1/2	  mutations.	  GBMs	  with	  oligodendroglial	  components	  are	  uniformly	  IDH1	  
mutated	  with	  chromosome	  1p/19q	  deletions.	  
GBM	  cells	  are	  highly	  migratory	  and	  transit	  through	  intercellular	  spaces,	  frequently	  
crossing	  the	  midline	  via	  the	  corpus	  callosum.	  The	  end	  result	  is	  a	  highly	  
disseminative	  but	  non-­‐metastatic	  tumor.	  The	  near-­‐universal	  recurrence	  GBM	  is	  also	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notable	  for	  the	  site	  of	  recurrence:	  Often	  but	  not	  exclusively	  the	  tumor	  recurs	  in	  a	  
2cm	  radius	  from	  the	  periphery	  of	  the	  original	  tumor	  [12].	  These	  two	  key	  features	  of	  
GBM	  –	  the	  near-­‐universal	  recurrence	  of	  disease	  and	  the	  highly	  invasive	  cellular	  
component	  –	  have	  been	  neatly	  explained	  by	  invoking	  the	  cancer	  stem	  cell	  hypothesis.	  
	  
A	  Brief	  History	  of	  the	  Cancer	  Stem	  Cell	  Hypothesis	  
Very	  briefly,	  the	  cancer	  stem	  cell	  hypothesis	  refers	  only	  to	  the	  hierarchy	  of	  cells	  
present	  within	  a	  given	  tumor.	  Responsible	  for	  the	  initiation	  of	  each	  and	  every	  solid	  
and	  liquid	  tumor	  is	  a	  cellular	  subpopulation	  –	  and	  ultimately	  a	  single	  cell	  –	  with	  
features	  that	  are	  otherwise	  unique	  to	  true	  stem	  cells,	  among	  them	  self-­‐regeneration,	  
quiescence,	  and	  (at	  least)	  multipotency.	  The	  stem-­‐like	  cell	  subpopulation	  of	  a	  tumor	  
need	  not	  be	  a	  large	  fraction	  –	  often	  less	  than	  1%	  in	  GBM	  [13]	  –	  but	  it	  is	  capable	  of	  
driving	  invasion,	  angiogenesis,	  metabolic	  reprogramming,	  survival	  in	  fastidious	  
conditions,	  and	  tumor	  growth	  in	  volume	  [14-­‐17].	  The	  consumptive	  component	  of	  
the	  tumor	  –	  the	  bulk,	  terminally	  differentiated	  cellular	  component	  –	  is	  the	  largest	  
contributor	  to	  tumor	  volume.	  
As	  mentioned	  earlier,	  cancer	  stem	  cells	  are	  used	  to	  explain	  tumor	  recurrence.	  While	  
radiation	  and	  chemotherapy	  may	  appear	  to	  decrease	  a	  tumor’s	  volume	  according	  to	  
imaging	  studies,	  at	  least	  a	  share	  of	  cancer	  stem	  cells	  have	  survived	  by	  virtue	  of	  
resistance.	  These	  surviving	  cancer	  stem	  cells	  then	  can	  repopulate	  the	  tumor,	  which	  
now	  has	  resistance	  to	  the	  original	  chemotherapeutic	  drug.	  It	  therefore	  becomes	  
clear	  that	  treatment	  of	  the	  disease	  with	  a	  single	  or,	  more	  likely,	  many	  compounds	  
which	  have	  deleterious	  effects	  on	  cancer	  stem	  cells	  is	  necessary	  [18].	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Of	  note,	  the	  cancer	  stem	  cell	  hypothesis	  does	  not	  seek	  to	  draw	  an	  absolute	  
connection	  between	  normal	  stem	  cells	  and	  cancer	  stem	  cells.	  In	  the	  case	  of	  pediatric	  
tumors,	  cancer	  stem	  cells	  may	  be	  derived	  directly	  from	  normal	  stem	  cells.	  In	  the	  
case	  of	  adult	  tumors,	  however,	  it	  is	  much	  more	  likely	  for	  a	  terminally	  differentiated	  
or	  transitional	  glial	  cell	  to	  acquire	  a	  single	  or	  set	  of	  oncogenic	  mutations	  which	  
propels	  it	  toward	  a	  multipotent,	  stem-­‐like	  state	  [19].	  
	  
The	  Cancer	  Stem	  Cell	  Hypothesis	  in	  GBM	  
As	  discussed	  above,	  the	  cancer	  stem	  cell	  hypothesis	  has	  emerged	  as	  a	  possible	  
explanation	  for	  chemotherapeutic	  and	  radiation	  resistance	  and,	  ultimately,	  tumor	  
recurrence	  and	  patient's	  death	  [20].	  In	  GBM,	  the	  cancer	  stem	  cell	  compartment	  has	  
alternately	  been	  referred	  to	  as	  “brain	  cancer	  stem	  cells”,	  “brain	  cancer	  stem-­‐like	  
cells”,	  and	  “brain	  tumor-­‐initiating	  cells”.	  	  Given	  that	  these	  same	  cells	  have	  features	  
similar	  to	  primitive	  neural	  stem	  cells,	  we	  prefer	  “brain	  cancer	  stem	  cells”	  (hereafter,	  
“BCSCs”)	  [21].	  
In	  all	  cases,	  this	  subpopulation	  shows	  capacity	  for	  asymmetric,	  self-­‐renewing	  
division	  and	  is	  (contentiously,	  [22])	  shown	  to	  express	  CD133	  (prominin	  1)	  at	  its	  
surface	  [23].	  BCSCs	  are	  capable	  of	  a)	  establishing	  tumors	  in	  vivo	  from	  a	  small	  
inoculum	  (<1,000	  cells)	  that	  are	  histologically	  identical	  to	  the	  tumors	  from	  which	  
they	  were	  isolated	  –	  complete	  with	  necrosis,	  vascular	  proliferation,	  and	  cellular	  
atypia	  and	  mitotic	  figures.	  Further,	  BCSCs	  can	  proliferate	  and	  form	  neurospheres	  
when	  grown	  in	  vitro	  in	  fastidious	  serum-­‐free	  conditions	  [23],	  and	  this	  cellular	  
subpopulation	  also	  expands	  under	  hypoxic	  conditions	  [17].	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Many	  of	  the	  bulk	  properties	  of	  GBM	  can	  be	  explained	  by	  BCSCs.	  It	  has	  become	  
increasingly	  clear	  that	  the	  BCSC	  subpopulation	  of	  GBM	  drives	  tumor	  progression,	  
promotes	  angiogenesis,	  and	  influences	  tumor	  cell	  migration.	  In	  vitro,	  BCSCs	  are	  
clearly	  resistant	  to	  both	  conventional	  chemotherapeutics	  [18],	  including	  
carboplatin,	  cisplatin,	  paclitaxel,	  doxorubicin,	  vincristine,	  methotrexate,	  and	  
temozolomide	  and	  radiotherapy	  [24]	  at	  clinically	  relevant	  dosages.	  Based	  on	  these	  
in	  vitro	  studies,	  which	  employed	  excessively	  high	  concentrations	  of	  drug,	  it	  seems	  
that	  even	  if	  conventional	  chemotherapeutics	  were	  combined	  with	  an	  ideal	  delivery	  
vehicle	  (a	  challenge	  discussed	  later),	  better	  outcomes	  would	  not	  result.	  
	  
Genetic	  Heterogeneity	  of	  GBM	  
Substantial	  genome	  sequencing	  and	  gene	  expression	  profiling	  has	  been	  performed	  
on	  hundreds	  of	  GBM	  tumor	  samples,	  with	  the	  goal	  being	  identification	  of	  common	  
thread	  genes	  or	  actionable	  pathways.	  What	  has	  emerged	  from	  this	  research	  is	  the	  
insight	  that	  histologically	  identical	  GBMs	  can	  have	  very	  different	  genetic	  signatures	  
(intertumoral	  heterogeneity)	  [7].	  
Four	  particular	  genetic	  subtypes	  have	  emerged	  from	  this	  line	  of	  research,	  termed	  
neural,	  proneural,	  mesenchymal,	  and	  classical	  [25].	  Acknowledgment	  of	  this	  
knowledge	  is	  important	  going	  forward	  in	  the	  development	  of	  novel	  GBM	  
therapeutics	  –	  it	  is	  now	  clear,	  based	  on	  this	  information	  and	  new	  information	  from	  a	  
variety	  of	  cancer	  types,	  that	  efficacy	  of	  a	  given	  agent	  in	  a	  tumor	  is	  not	  guaranteed	  in	  
its	  histologically	  identical	  counterpart.	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GBM	  treatment	  –	  and	  indeed	  the	  treatment	  of	  every	  solid	  tumor	  –	  is	  further	  
complicated	  by	  the	  genetic	  heterogeneity	  found	  within	  a	  tumor	  (intratumoral	  
heterogeneity).	  First	  explained	  in	  the	  context	  of	  renal	  cell	  carcinoma	  [26],	  it	  is	  now	  
clear	  that	  cells	  isolated	  from	  distinct	  regions	  of	  a	  given	  GBM	  tumor	  bear	  grossly	  
different	  expression	  signatures	  but	  appear	  to	  be	  descended	  from	  a	  common	  
progenitor	  [27].	  	  The	  exact	  explanatory	  power	  of	  the	  cancer	  stem	  cell	  hypothesis	  in	  
this	  situation	  remains	  to	  be	  seen,	  as	  independent	  cancer	  stem	  cell	  subpopulations	  
from	  distinct	  parts	  of	  GBMs	  have	  not	  been	  isolated	  and	  rigorously	  examined.	  What	  
is	  clear,	  however,	  is	  that	  both	  inter-­‐	  and	  intratumoral	  heterogeneity	  must	  be	  
explored	  and,	  possibly,	  accounted	  for	  in	  future	  drug	  discovery	  efforts.	  
	  
A	  Brief	  History	  of	  GBM	  Therapeutics	  and	  Evolution	  of	  Outcomes	  
Despite	  years	  of	  research	  into	  molecular	  and	  cellular	  mechanisms	  as	  well	  as	  
countless	  chemo-­‐	  and	  radiotherapeutic	  trials,	  median	  overall	  survival	  times	  have	  
remained	  near-­‐constant	  since	  the	  introduction	  of	  radiation	  therapy	  [28].	  Indeed,	  the	  
oldest	  management	  method,	  surgery,	  is	  the	  single	  greatest	  determinant	  of	  extent	  of	  
patient	  survival	  [2].	  
Originally,	  chemotherapeutic	  options	  included	  bis-­‐chloroethylnitrosurea	  (also	  
referred	  to	  as	  carmustine,	  BCNU,	  mustard	  gas,	  [29])	  and	  the	  chemotherapeutic	  
regimen	  of	  procarbazine,	  lomustine,	  and	  vincristine	  (also	  referred	  to	  as	  PCV,	  [30])	  –	  
both	  of	  these	  regimens	  utilize	  pre-­‐1960s	  chemotherapeutics	  known	  to	  be	  
untargeted,	  acting	  instead	  at	  the	  level	  of	  nucleic	  acid	  polymerization	  and	  dNTP	  
synthesis.	  Intrathecal,	  intravenous,	  oral,	  and	  convection-­‐enhanced	  methods	  of	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chemotherapeutic	  delivery	  have	  been	  attempted	  in	  the	  past,	  and,	  not	  surprisingly,	  
none	  produced	  substantial	  gains	  in	  overall	  survival	  in	  GBM	  [31].	  Controlled-­‐release	  
delivery	  of	  BCNU	  in	  the	  form	  of	  the	  Gliadel®	  wafer	  had	  a	  small	  but	  significant	  
benefit	  on	  survival	  [32-­‐34].	  First-­‐generation	  chemotherapeutics,	  as	  well	  as	  Gliadel®,	  
have	  proven	  beneficial	  in	  the	  treatment	  of	  low-­‐grade	  glioma	  and	  anaplastic	  
astrocytoma	  but	  have	  had	  only	  very	  limited	  benefit	  in	  the	  treatment	  of	  GBM.	  
Delivery	  methods	  mentioned	  above,	  including	  issues	  raised	  by	  their	  failures,	  will	  be	  
discussed	  later	  in	  the	  Introduction.	  
Most	  notably,	  GBM	  treatment	  went	  through	  a	  sea	  change	  in	  2005	  with	  the	  FDA’s	  
approval	  of	  temozolomide	  (trade	  name	  Temodar®).	  Temozolomide	  is	  a	  cytotoxic	  
drug	  responsible	  for	  site-­‐specific	  inhibition	  of	  methylguaninemethyltransferase	  
[MGMT];	  this	  specificity	  produces	  an	  improved	  side	  effect	  profile	  and	  roughly	  25%	  
benefit	  in	  median	  survival	  time	  as	  well	  as	  five-­‐fold	  increase	  in	  long-­‐term	  survivors	  
when	  compared	  to	  placebo	  control	  [35,	  36].	  While	  MGMT	  hypermethylation	  is	  an	  
independent	  predictor	  of	  survival	  in	  GBM,	  and	  radiation	  therapy	  improves	  
outcomes	  in	  both	  hypermethylated	  and	  non-­‐methylated	  MGMT	  promoter	  [37],	  
temozolomide’s	  survival	  benefit	  is	  seen	  in	  both	  types	  of	  tumors.	  However,	  the	  
survival	  benefit	  of	  temozolomide	  administration	  is	  further	  magnified	  in	  tumors	  with	  
hypermethylated	  MGMT	  promoters	  and	  resultant	  diminished	  MGMT	  expression	  [1,	  
37,	  38].	  Temozolomide,	  radiation	  therapy,	  and,	  most	  importantly,	  maximal	  surgical	  
resection	  have	  subsequently	  become	  the	  backbone	  of	  every	  therapeutic	  regimen	  
since.	  Dosing	  schedules	  of	  temozolomide	  are	  variable	  and	  highly	  customizable	  
depending	  on	  clinical	  context.	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More	  recent	  efforts	  have	  focused	  upon	  extending	  the	  use	  of	  anti-­‐angiogenic	  therapy,	  
namely	  anti-­‐vascular	  endothelial	  growth	  factor	  monoclonal	  antibody	  bevacizumab,	  
to	  GBM	  treatment.	  First	  approved	  by	  the	  FDA	  for	  recurrent	  GBM	  in	  2009,	  
bevacizumab	  has	  not	  been	  as	  efficacious	  as	  hoped;	  indeed,	  the	  European	  Union	  has	  
not	  approved	  bevacizumab	  for	  GBM	  [39].	  Bevacizumab,	  by	  virtue	  of	  decreasing	  
vasculature,	  leads	  to	  an	  improvement	  in	  imaging	  results	  but	  no	  concomitant	  
approval	  in	  survival.	  Necessarily,	  this	  leads	  to	  improvement	  in	  progression-­‐free	  
survival	  but	  no	  improvement	  in	  overall	  survival.	  More	  recently,	  up-­‐front	  
bevacizumab	  for	  newly	  diagnosed	  GBM	  has	  been	  tested	  in	  both	  US	  and	  European	  
trials	  (RTOG0825	  and	  Avaglio,	  respectively).	  Preliminary	  reports	  from	  these	  trials	  
presented	  at	  the	  2013	  World	  Federation	  of	  Neuro-­‐oncology	  Quadrennial	  Meeting	  
suggest	  that	  there	  is	  zero	  overall	  survival	  benefit,	  but	  significant	  benefit	  in	  
progression-­‐free	  survival,	  as	  well	  as	  slower	  deterioration	  of	  Karnofsky	  Performance	  
Status	  and	  longer	  time	  to	  initiation	  of	  steroid	  treatment	  with	  addition	  of	  
bevacizumab.	  
There	  appear	  to	  be	  marginal	  benefits	  to	  addition	  of	  bevacizumab,	  mainly	  in	  the	  
arena	  of	  quality	  of	  life,	  but	  at	  the	  level	  of	  the	  tumor	  there	  appear	  to	  be	  at	  least	  two	  
substantial	  drawbacks	  to	  anti-­‐angiogenic	  initiation.	  First,	  vascular	  permeability	  
decreases	  with	  bevacizumab	  treatment,	  leading	  to	  even	  more	  difficult	  blood-­‐brain	  
barrier	  penetration.	  Second,	  evidence	  in	  other	  tumor	  types	  suggest	  an	  expansion	  of	  
the	  cancer	  stem	  cell	  subpopulation	  in	  response	  to	  hypoxia	  [40].	  Though	  this	  finding	  
has	  not	  been	  duplicated	  in	  GBM	  and	  BCSCs,	  the	  idea	  merits	  further	  investigation.	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Temozolomide	  is	  by	  conventional	  definitions	  a	  “good”	  drug,	  but	  it	  remains	  
powerless	  to	  overcome	  GBM	  on	  its	  own.	  Indeed,	  despite	  years	  of	  honing	  and	  
customizing	  current	  standard	  of	  care	  treatment	  (maximal	  safe	  surgical	  resection,	  
radiation,	  and	  oral	  temozolomide),	  median	  survival	  following	  GBM	  diagnosis	  
remains	  a	  dismal	  14.6	  months	  [35],	  and	  the	  five-­‐year	  survival	  rate	  is	  less	  than	  10%	  
[41].	  Discouragingly,	  the	  vast	  majority	  of	  GBMs	  recur	  within	  2	  cm	  of	  the	  original	  
tumor	  focus	  [12].	  
What	  becomes	  clear	  from	  this	  overview	  is	  that	  1)	  GBM	  has	  seen	  quite	  modest	  
improvements	  in	  outcomes	  and	  2)	  therapeutic	  insight	  has	  not	  flowed	  from	  scientific	  
understanding.	  The	  failures	  of	  current	  GBM	  treatments	  has	  been	  attributed	  not	  to	  a	  
lack	  of	  understanding	  of	  the	  disease	  process	  but	  to	  a	  lack	  of	  efficient,	  disseminated,	  
and	  lasting	  drug	  delivery	  and	  the	  absence	  of	  chemotherapeutic	  drugs	  with	  efficacy	  
against	  the	  relative	  cellular	  subpopulation	  [42].	  Simply	  put,	  to	  date	  we	  have	  not	  
made	  appropriate	  use	  of	  our	  knowledge.	  
	  
GBM	  Treatment	  Challenges:	  Drug	  Delivery	  Problem	  and	  Potential	  Solutions	  
Nanocarrier-­‐Mediated	  Drug	  Delivery	  in	  CNS	  Disease	  
Within	  the	  realm	  of	  drug	  delivery,	  one	  major	  obstacle	  to	  treating	  GBM	  is	  the	  blood-­‐
brain	  barrier	  [43].	  The	  blood-­‐brain	  barrier,	  while	  known	  to	  be	  weaker	  and	  more	  
permeable	  in	  diseased	  states,	  largely	  prevents	  the	  entrance	  of	  highly	  polar	  and	  large	  
chemical	  compounds	  into	  brain	  parenchyma.	  Indeed,	  the	  blood-­‐brain	  barrier	  greatly	  
limits	  the	  extravasation	  of	  compounds	  greater	  than	  500	  Daltons	  in	  molecular	  weight	  
[44].	  Additionally,	  polar	  compounds	  have	  been	  largely	  excluded.	  Small	  molecules	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like	  temozolomide	  and	  carmustine	  are	  capable	  of	  crossing	  the	  blood-­‐brain	  barrier,	  
albeit	  inefficiently	  [45],	  but	  fail	  for	  both	  delivery-­‐	  and	  cellular	  sensitivity-­‐related	  
reasons.	  
The	  blood-­‐brain	  barrier	  can	  be	  bypassed	  altogether	  with	  direct,	  locoregional	  
delivery	  of	  therapeutic	  agents	  either	  through	  catheter-­‐based	  systems	  or	  
implantation	  at	  the	  site	  of	  surgical	  resection.	  	  Initial	  work	  under	  this	  paradigm	  
focused	  on	  the	  local	  implantation	  of	  a	  drug-­‐loaded	  biodegradable	  polymer	  wafer	  
(Gliadel®),	  which	  enables	  controlled	  release	  of	  carmustine	  over	  a	  prolonged	  period	  
of	  time.	  	  However,	  the	  use	  of	  the	  Gliadel®	  wafer	  can	  only	  modestly	  improve	  GBM	  
patient	  survival,	  typically	  by	  2	  months	  [34].	  An	  experimental	  study	  suggested	  that,	  
although	  these	  implants	  are	  able	  to	  achieve	  persistently	  high	  interstitial	  drug	  
concentrations	  at	  the	  tumor	  site,	  there	  is	  poor	  drug	  penetration	  beyond	  the	  tumor	  
margin,	  which	  thereby	  limits	  their	  efficacy	  [46].	  Of	  course,	  in	  the	  design	  of	  these	  
trials,	  patients	  are	  those	  who	  have	  failed	  multiple	  initial	  treatment	  regimens,	  
including	  intravenous	  BCNU	  and	  PCV.	  That	  is	  to	  say,	  one	  potential	  reason	  for	  the	  
relatively	  small	  survival	  benefit	  in	  these	  patients	  is	  the	  high	  likelihood	  that	  their	  
tumors	  have	  acquired	  chemotherapeutic	  resistance	  from	  previous	  exposures,	  or	  a	  
chemotherapeutic-­‐resistant	  clone	  has	  come	  to	  predominate	  the	  bulk	  tumor	  
population.	  
Polymeric	  wafer	  implants	  highlighted	  a	  second	  issue	  with	  contemporary	  
therapeutics:	  	  the	  drug	  released	  from	  the	  wafer	  relies	  solely	  on	  passive	  diffusion	  to	  
reach	  target	  cells.	  As	  a	  result,	  there	  is	  poor	  drug	  penetration	  of	  parenchyma	  outside	  
of	  the	  tumor	  cavity	  [47-­‐50].	  Additionally,	  penetration	  of	  a	  distant	  tumor	  focus	  by	  the	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small	  amount	  of	  free	  drug	  that	  does	  diffuse	  beyond	  the	  surgical	  margin	  is	  likely	  to	  be	  
markedly	  decreased	  by	  the	  outward	  convective	  flow	  of	  fluid	  at	  the	  tumor	  periphery.	  
The	  treatment	  of	  GBM	  would	  therefore	  be	  improved	  by	  strategies	  that	  a)	  enhance	  
the	  depth	  of	  penetration	  of	  locally	  delivered	  therapeutic	  agents	  and	  b)	  overcome	  the	  
problem	  of	  outward	  convective	  fluid	  flow.	  	  	  
Convection-­‐enhanced	  delivery	  (hereafter,	  “CED”)	  is	  a	  promising	  approach	  to	  
overcome	  the	  limited	  distribution	  volume	  associated	  with	  diffusion-­‐based	  delivery	  
systems.	  For	  diffusion-­‐based	  delivery,	  drug	  molecules	  move	  passively	  from	  regions	  
of	  high	  concentration	  to	  regions	  of	  lower	  concentration.	  As	  a	  result,	  large	  molecules	  
such	  as	  antibodies	  diffuse	  no	  more	  than	  1	  mm	  in	  3	  days,	  and	  small	  drugs	  that	  may	  
have	  better	  diffusion	  are	  often	  quickly	  eliminated	  by	  capillary	  clearance	  or	  
metabolism.	  In	  contrast,	  for	  dispersion	  using	  convection,	  agents	  are	  delivered	  to	  the	  
brain	  via	  flow	  through	  a	  cannula	  under	  constant	  pressure.	  In	  this	  scenario,	  the	  
dispersion	  of	  agents	  is	  powered	  by	  bulk	  flow	  kinetics	  or	  gradients	  of	  pressure,	  in	  
addition	  to	  gradient	  of	  concentrations.	  As	  a	  result,	  it	  is	  possible	  to	  distribute	  agents	  
widely	  in	  the	  brain.	  
Bobo	  and	  colleagues	  at	  the	  NIH	  first	  reported	  CED	  to	  the	  brain	  [51].	  Since	  then,	  CED	  
has	  been	  used	  in	  clinical	  trials,	  but	  this	  experience	  has	  revealed	  some	  limitations.	  
Conventional	  CED	  of	  drug	  solutions	  results	  in	  an	  increased	  depth	  of	  penetration,	  but	  
these	  results	  are	  transient.	  Free	  drugs	  are	  subject	  to	  high	  rates	  of	  elimination	  (i.e.	  
they	  are	  diluted	  into	  cerebrospinal	  fluid	  or	  blood	  or	  taken	  up	  by	  capillaries)	  or	  they	  
are	  high	  short	  half-­‐lives	  in	  the	  brain:	  therefore,	  they	  disappear	  soon	  after	  the	  
infusion	  stops	  [52].	  This	  phenomenon	  could	  explain	  the	  failure	  of	  the	  recent	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PRECISE	  trial,	  in	  which	  a	  potent	  targeted	  toxin,	  cintredekin	  besudotox	  (IL13-­‐
PE38QQR)	  in	  suspension,	  was	  delivered	  to	  brain	  tumors	  via	  CED	  but	  failed	  to	  show	  
advantage	  when	  compared	  to	  diffusion-­‐based	  Gliadel®	  wafers	  [53-­‐55].	  To	  
overcome	  the	  limitations	  of	  CED,	  agents	  can	  be	  loaded	  into	  nanocarriers,	  such	  as	  
liposomes,	  micelles,	  dendrimers	  or	  polymeric	  nanoparticles,	  which	  have	  small	  sizes	  
to	  allow	  for	  distribution	  in	  brain,	  but	  can	  protect	  therapeutic	  agents	  from	  loss	  and	  
control	  their	  release	  for	  long	  periods	  after	  infusion	  (Figure	  2).	  
Nanoparticle	  delivery	  systems	  for	  drugs	  have	  been	  available	  for	  many	  years	  [56].	  	  
Many	  research	  groups	  focus	  on	  the	  use	  of	  nanoparticles	  introduced	  systemically,	  
with	  the	  hopes	  that	  some	  of	  these	  particles	  will	  enter	  the	  brain	  through	  the	  BBB.	  	  
This	  approach	  appears	  to	  work	  in	  some	  cases,	  although	  the	  percentage	  of	  
intravenously	  administered	  particles	  that	  enter	  the	  brain	  is	  very	  low,	  with	  fewer	  1%	  
of	  particles	  entering	  the	  parenchyma,	  and	  the	  problems	  associated	  with	  diffusion-­‐
based	  delivery	  persist.	  It	  is	  not	  yet	  clear	  whether	  sufficient	  quantities	  of	  drug	  can	  be	  
delivered	  by	  systemically-­‐administered	  nanoparticles	  to	  make	  this	  a	  useful	  method	  
for	  treating	  tumors	  in	  the	  brain	  (although	  there	  is	  some	  evidence	  nanoparticles	  may	  
be	  useful	  for	  diagnostic	  purposes,	  such	  as	  iron	  oxide-­‐containing	  nanoparticles	  that	  
facilitate	  imaging	  of	  brain	  tumors	  [57]).	  	  An	  alternate,	  and	  we	  believe	  substantially	  
more	  aggressive,	  approach	  is	  to	  deliver	  the	  nanoparticles	  directly	  into	  the	  brain,	  
perhaps	  using	  CED	  to	  facilitate	  the	  distribution	  of	  the	  nanoparticles	  throughout	  the	  
volume	  of	  the	  brain	  that	  needs	  therapy.	  	  
Polymeric	  nanoparticles	  can	  be	  delivered	  via	  CED	  to	  treat	  brain	  tumors.	  In	  a	  recent	  
study,	  CED	  of	  camptothecin-­‐loaded	  nanoparticles	  led	  to	  longer	  survival	  in	  animals	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with	  intracranial	  tumors	  than	  CED	  of	  camptothecin	  alone	  [58].	  However,	  prior	  
efforts	  to	  deliver	  polymer	  nanoparticles	  via	  CED	  have	  achieved	  limited	  volume	  of	  
distribution,	  due	  to	  large	  diameters	  that	  limit	  interstitial	  convective	  transport	  [58-­‐
60].	  The	  pore	  size	  of	  normal	  brain	  interstitial	  space	  is	  between	  40	  and	  60nm	  [61]	  
while	  it	  is	  ~70-­‐100	  nm	  within	  a	  tumor	  in	  the	  brain	  [62]:	  these	  pore	  sizes	  suggest	  
that	  nanoparticles	  for	  CED	  to	  intracranial	  tumors	  should	  be	  60-­‐80	  nm	  in	  diameter,	  
to	  leverage	  size-­‐exclusion	  and	  allow	  for	  access	  to	  tumor-­‐burdened	  parenchyma	  
while	  limiting	  access	  to	  normal	  brain.	  
	  
Development	  of	  Highly-­‐Penetrative	  Polymeric	  Nanocarrier	  System	  
Central	  nervous	  system	  drug	  delivery	  took	  a	  large	  step	  forward	  with	  the	  
development	  of	  the	  highly-­‐penetrative	  polymeric	  nanocarrier	  platform	  by	  our	  
laboratory	  in	  a	  parallel	  and	  complementary	  project	  [21,	  63].	  Invoking	  the	  concept	  of	  
CED	  of	  polymeric	  nanocarriers	  capable	  of	  controlled	  release	  of	  drug	  payload,	  our	  
laboratory	  has	  constructed	  a	  nanocarrier	  system	  composed	  of	  poly(lactic-­‐co-­‐
glycolic)	  acid,	  the	  same	  FDA-­‐approved	  co-­‐polymer	  used	  in	  biodegradable	  sutures.	  
When	  loaded	  with	  coumarin-­‐6	  fluorescent	  dye	  and	  injected	  into	  rat	  brains	  using	  
CED,	  the	  nanocarriers	  disperse	  into	  a	  volume	  roughly	  four-­‐fold	  larger	  than	  the	  
volume	  infused.	  Compared	  to	  the	  smallest	  previously	  published	  nanoparticles,	  this	  
represents	  a	  roughly	  two-­‐and-­‐one-­‐half-­‐fold	  increase	  in	  penetration.	  Further,	  the	  
surface	  of	  the	  highly-­‐penetrative	  polymeric	  nanocarrier	  system	  can	  be	  
biochemically	  modified	  to	  contain	  ligands	  with	  activity	  in	  PET.	  When	  delivered	  in	  a	  
porcine	  brain	  (a	  brain	  much	  larger	  than	  that	  of	  a	  rat	  but	  still	  smaller	  than	  that	  of	  a	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human),	  the	  volume	  ratios	  remains	  a	  similar	  figure	  and,	  importantly,	  the	  
nanoparticles	  can	  penetrate	  the	  all-­‐important	  2cm	  radius	  needed	  to	  prevent	  the	  
majority	  of	  GBM	  recurrences.	  Altogether,	  these	  data	  show	  that	  1)	  relatively	  
widespread	  and	  clinically-­‐relevant	  distribution	  of	  polymeric	  nanocarriers	  is	  
possible	  and	  2)	  real-­‐time	  tracking	  of	  highly-­‐penetrative	  polymeric	  nanocarriers	  is	  
feasible.	  Finally,	  these	  findings	  show	  that	  the	  highly-­‐penetrative	  polymeric	  
nanocarrier	  system	  is	  an	  advantageous	  platform	  for	  rapid	  in	  vivo	  translation	  of	  
candidate	  small	  molecule	  compounds	  and	  raise	  the	  possibility	  that	  if	  it	  were	  loaded	  
with	  an	  appropriate	  compound,	  the	  system	  could	  help	  to	  prevent	  recurrence	  of	  
GBM.	  
	  
Imaging	  of	  Polymeric	  Nanoparticles	  
Accurate	  measurement	  of	  the	  distribution	  of	  a	  delivered	  agent	  is	  needed	  to	  assess	  
drug	  or	  gene	  delivery	  in	  GBM.	  A	  number	  of	  methods	  have	  been	  employed;	  most	  
relevant	  to	  our	  work	  are	  MRI	  and	  PET.	  
Drug	  distribution	  is	  quantified	  by	  MRI	  using	  gadolinium-­‐based	  contrast	  agents	  [64].	  
Contrast	  provided	  by	  gadolinium	  agents,	  such	  as	  gadolinium-­‐diethylene	  triamine	  
pentaacetic	  acid	  (Gd-­‐DTPA),	  can	  be	  used	  to	  monitor	  disruption	  of	  the	  blood-­‐brain	  
barrier	  [64],	  and	  when	  co-­‐administered	  with	  a	  therapeutic	  agent	  or	  other	  
macromolecule,	  can	  be	  used	  to	  directly	  assess	  the	  volume	  of	  drug	  delivery.	  Relevant	  
to	  our	  work,	  gadolinium	  complexes	  have	  been	  encapsulated	  in	  polymeric	  
nanocarriers,	  such	  as	  polymer	  nanoparticles	  for	  the	  purpose	  of	  studying	  drug	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distribution	  [65].	  This	  approach	  is	  appealing,	  but	  its	  accuracy	  may	  be	  limited	  by	  the	  
release	  and	  additional	  diffusivity	  of	  gadolinium	  [66].	  	  
Positron-­‐emission-­‐tomography	  (PET)	  is	  another	  promising	  modality	  for	  imaging	  
drug	  delivery	  to	  tumors,	  albeit	  a	  more	  expensive	  one	  than	  MRI.	  PET	  tracers	  can	  be	  
infused	  concurrently	  with	  drug	  or	  bound	  to	  the	  delivery	  system,	  as	  shown	  in	  our	  
highly-­‐penetrative	  polymeric	  nanocarriers	  [21].	  Overlaying	  PET	  with	  CT	  allows	  for	  
anatomical	  assignment	  of	  drug	  distribution.	  Additionally,	  by	  virtue	  of	  using	  
metabolically	  active	  amino	  acid	  tracers,	  PET	  may	  allow	  for	  finer	  resolution	  and	  
more	  accurate	  estimation	  of	  the	  leading	  edge	  of	  the	  tumor	  [67,	  68].	  While	  PET	  
certainly	  has	  advantages	  –	  and	  may	  well	  be	  useful	  as	  a	  one-­‐time	  imaging	  study	  early	  
in	  the	  therapeutic	  process	  –	  it	  remains	  an	  expensive,	  radiation-­‐laden,	  and	  very	  
short-­‐lived	  technique	  [69].	  For	  the	  purposes	  of	  following	  a	  polymeric	  nanocarrier	  
over	  a	  time	  period	  relevant	  to	  its	  controlled-­‐release	  kinetics,	  MRI	  is	  a	  superior	  
methodology.	  
	  
GBM	  Treatment	  Challenges:	  Drug	  Discovery	  
Automated	  HTS	  for	  Identification	  of	  GBM	  Treatments	  
Assuming	  the	  development	  of	  an	  ideal	  drug	  delivery	  vehicle	  that	  can	  be	  followed	  in	  
real-­‐time	  using	  non-­‐invasive	  and	  non-­‐destructive	  imaging	  techniques,	  we	  turn	  to	  
the	  question	  of	  payload.	  As	  evidenced	  by	  the	  cellular	  and	  genetic	  complexity	  of	  GBM,	  
an	  effective	  drug	  must	  be	  effective	  against	  not	  only	  a	  single	  BCSC	  population	  but	  
also	  multiple,	  diverse	  BCSC	  populations.	  An	  effective	  compound	  must	  inhibit	  both	  
arms	  of	  asymmetric	  cell	  division:	  the	  proliferation	  of	  GBM	  bulk	  tumor	  cells	  and	  the	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self-­‐renewal	  of	  BCSCs.	  In	  the	  event	  a	  compound	  does	  not	  kill	  BCSCs,	  it	  should	  
promote	  their	  differentiation	  into	  bulk	  tumor	  cells,	  which	  are	  more	  readily	  killed	  by	  
conventional	  chemotherapeutics	  (including	  temozolomide	  and	  carmustine)	  and,	  
barring	  dedifferentiation	  [22],	  unable	  to	  spur	  tumor	  recurrence.	  Additionally,	  we	  
should	  seek	  to	  identify	  compounds	  that	  have	  minimal	  deleterious	  effects	  against	  
normal	  cellular	  populations,	  including	  neural	  stem	  cells	  and	  normal	  glial	  cells.	  
Given	  the	  multiple	  cellular	  sensitivity	  requirements	  that	  must	  be	  met	  by	  a	  candidate	  
anti-­‐tumor	  compound,	  efficient	  discovery	  and	  clinical	  translation	  is	  a	  necessity.	  One	  
such	  method	  of	  identification,	  as	  previously	  mentioned,	  is	  high-­‐throughput	  
screening.	  Broadly	  speaking,	  high-­‐throughput	  compound	  screening	  is	  a	  system	  of	  
consecutive	  methods	  reliant	  upon	  careful	  planning	  and	  design,	  large-­‐scale	  
preparation,	  small	  volumes	  measured	  using	  carefully	  calibrated	  nanoscale	  
instrumentation,	  indirect	  measurement	  of	  effect	  (e.g.	  bioluminescence,	  fluorescence,	  
or	  computer-­‐assisted	  image	  interpretation	  used	  as	  a	  proxy	  for	  some	  property	  of	  the	  
cell	  population),	  and	  large-­‐scale	  statistical	  interpretation	  with	  the	  aim	  of	  
discovering	  and	  quantitating	  the	  effects	  of	  candidate	  compounds	  on	  something.	  	  
Within	  the	  context	  of	  drug	  discovery	  against	  a	  population	  of	  cells	  without	  a	  pre-­‐
defined	  molecular	  target,	  high-­‐throughput	  screening	  often	  takes	  the	  form	  of	  
exposing	  a	  characterized	  (and,	  optionally,	  immortalized)	  cell	  population	  to	  
thousands	  of	  compounds	  of	  various	  classes	  (FDA-­‐approved	  drugs,	  internationally-­‐
approved	  drugs,	  kinase	  and	  phosphatase	  inhibitors,	  natural	  products,	  or	  random	  
chemical	  backbones)	  and	  subsequently	  analyzing	  cell	  number	  using	  
bioluminescence,	  fluorescence,	  absorbance	  spectroscopy,	  or	  computer-­‐assisted	  cell	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counts	  after	  application	  of	  exogenous	  dye.	  In	  the	  case	  of	  a	  known	  molecular	  target,	  a	  
similar	  but	  more	  indirect	  experiment	  can	  be	  performed	  with	  a	  different	  readout	  
(e.g.	  fluorescence	  resonance	  energy	  transfer).	  
Given	  the	  obvious	  scientific	  and	  legal	  difficulties	  and	  expenses	  of	  shepherding	  a	  
novel	  compound	  through	  all	  necessary	  pre-­‐clinical	  testing	  and	  the	  FDA	  approval	  
process,	  one	  of	  the	  goals	  of	  a	  high-­‐throughput	  screening	  experiment	  is	  the	  
identification	  of	  new	  functions	  for	  public	  domain	  compounds	  with	  known	  
pharmacokinetics,	  pharmacodynamics,	  and	  toxicity,	  so	  called	  repurposing.	  Privately	  
held	  compounds	  can	  be	  repurposed,	  as	  well.	  In	  the	  event	  that	  a	  novel	  chemical	  
backbone	  is	  shown	  to	  have,	  for	  example,	  an	  anti-­‐cancer	  effect,	  downstream	  
synthetic	  and	  combinatorial	  chemistry	  can	  be	  performed	  to	  increase	  specificity	  and	  
efficacy,	  as	  well	  as	  improve	  clinically	  relevant	  properties	  like	  half-­‐life	  and	  solubility.	  
	  
High-­‐Throughput	  Screening	  Work	  Relevant	  to	  GBM	  
High-­‐throughput	  screening	  projects	  aimed	  at	  therapeutic	  discovery	  have	  been	  
undertaken	  in	  GBM,	  and,	  more	  specifically,	  BCSC	  and	  related	  systems.	  Initial	  efforts	  
in	  the	  high-­‐throughput	  screening	  of	  central	  nervous	  system	  disorders	  focused	  on	  
identification	  of	  proliferation	  and	  self-­‐renewal	  circuitry	  in	  mouse	  neural	  stem	  cells	  
[70].	  Building	  upon	  the	  broad	  functional	  similarities	  between	  neural	  stem	  cells	  and	  
cancer	  stem	  cells	  (self-­‐renewal	  and	  asymmetric	  division),	  a	  single	  primary	  mouse	  
neural	  stem	  cell	  line	  was	  screened	  for	  growth	  in	  response	  to	  known	  
pharmacologically	  active	  compounds.	  Follow-­‐up	  screening	  focused	  upon	  the	  self-­‐
renewal	  capacity	  of	  cells	  pre-­‐treated	  with	  growth	  inhibitory	  compounds	  as	  assessed	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by	  neurosphere	  assay.	  This	  work,	  although	  an	  admittedly	  small	  screen,	  was	  
important	  for	  its	  incorporation	  of	  normal	  glial	  cell	  control	  (mouse	  astrocytes),	  the	  
insight	  that	  compounds	  thought	  to	  be	  previously	  innocuous	  (including	  
neurotransmitters)	  could	  have	  broad	  effects	  on	  self-­‐renewal,	  and	  the	  realization	  that	  
high-­‐throughput	  screening	  of	  stem	  cell	  populations	  was	  in	  fact	  feasible.	  
Most	  recently,	  and	  relevant	  to	  our	  project,	  eight	  small	  molecules	  were	  identified	  
from	  a	  library	  of	  over	  30,000	  compounds	  [71].	  The	  aim	  of	  this	  project	  was	  to	  
identify	  compounds	  acting	  specifically	  at	  the	  level	  of	  BCSCs;	  therefore	  it	  utilized	  
parallel	  screens	  of	  BCSCs	  and	  tumor	  matched	  bulk	  differentiated	  tumor	  cells.	  The	  
weaknesses	  of	  this	  particular	  project	  were	  its	  lack	  of	  downstream	  characterization	  
of	  compounds,	  an	  obvious	  inability	  to	  deliver	  the	  compounds	  (instead	  relying	  on	  
pre-­‐treatment	  inoculation	  models	  to	  “prove”	  in	  vivo	  activity),	  and	  lack	  of	  a	  normal	  
cell	  population	  control	  (neural	  stem	  cell	  or	  normal	  glial	  cell).	  Most	  notable,	  however,	  
is	  the	  lack	  of	  characterization	  of	  cell	  lines:	  the	  authors	  do	  not	  prove	  that	  these	  cell	  
lines	  are	  different	  from	  one	  another	  or	  that	  the	  known	  intertumoral	  genetic	  
heterogeneity	  of	  GBM	  is	  comprised	  between	  them,	  calling	  into	  question	  the	  
therapeutic	  generalizability	  of	  their	  findings.	  That	  said,	  in	  addition	  to	  showing	  the	  
feasibility	  of	  high-­‐throughput	  screens	  in	  the	  context	  of	  cancer	  stem	  cells	  (a	  cell	  
system	  with	  numerous	  technical	  challenges	  including	  slow	  growth,	  non-­‐adherence,	  
and	  expensive	  growth	  factor	  supplementation),	  the	  work	  is	  an	  important	  first	  step	  
by	  virtue	  of	  its	  identification	  of	  compounds	  which	  could	  be	  repurposed	  for	  GBM	  
treatment	  and	  for	  the	  use	  of	  an	  appropriate	  control	  (tumor-­‐matched	  bulk	  tumor	  
cell).	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RNA	  interference,	  in	  the	  form	  of	  short	  interfering	  RNA	  (siRNA),	  is	  an	  in	  vogue	  
experimental	  modality	  that	  specifically	  “knocks	  down”	  gene	  expression	  through	  
delivery	  of	  a	  double-­‐stranded	  RNA	  molecule	  that	  is	  ultimately	  processed	  into	  a	  
single	  strand	  and	  binds	  to	  a	  complementary	  mRNA	  sequence.	  RNAi’s	  use	  as	  a	  
therapeutic	  modality	  is	  limited	  by	  expense,	  rapid	  degradation,	  and	  delivery,	  but	  its	  
use	  as	  a	  research	  tool	  is	  undeniable.	  Within	  the	  realm	  of	  GBM	  and	  BCSCs,	  recent	  
RNAi-­‐based	  work	  has	  focused	  on	  identifying	  single	  kinases	  and	  phosphatases	  with	  
effects	  on	  differentiation	  of	  BCSCs.	  This	  work	  builds	  on	  the	  insight	  that	  
differentiating	  BCSCs	  and	  ridding	  them	  of	  their	  capacities	  for	  self-­‐renewal	  and	  
asymmetric	  division	  while	  also	  increasing	  sensitivity	  to	  apoptosis.	  The	  major	  
weakness	  of	  this	  set	  of	  experiments	  is	  the	  limited	  number	  of	  genes	  being	  tested	  and,	  
similar	  to	  the	  projects	  above,	  the	  lack	  of	  therapeutic	  proof	  for	  the	  identified	  gene	  
and	  siRNA.	  
In	  recent	  work	  [72],	  we	  have	  performed	  a	  whole-­‐genome	  siRNA	  screen	  on	  a	  
characterized	  BCSC	  line	  in	  search	  of	  genes	  which,	  in	  response	  to	  decreased	  
expression,	  lead	  to	  decreased	  stemness	  (as	  measured	  by	  nestin	  expression)	  and	  
increased	  differentiation	  (as	  measured	  by	  glial	  fibrillary	  acidic	  protein	  expression	  
and	  length:width	  ratio,	  a	  proxy	  for	  elongated	  mesenchymal	  phenotype	  of	  bulk	  
tumor	  cells).	  The	  work	  is	  important	  for	  its	  scope	  and	  for	  the	  technical	  achievement	  
of	  its	  use	  of	  automated	  imaging.	  What	  remains	  to	  be	  seen	  is	  the	  therapeutic	  role	  that	  
these	  siRNA	  molecules	  can	  have	  going	  forward.	  
Altogether,	  these	  early	  successes	  suggest	  that	  high-­‐throughput	  screening	  is	  a	  
promising	  approach	  for	  identifying	  novel	  BCSC-­‐targeted	  therapeutics.	  The	  intent	  of	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this	  project	  is	  to	  focus	  upon	  small	  molecule	  screening,	  as	  it	  is	  clear	  that	  the	  universe	  
of	  previously	  characterized	  chemical	  compounds	  has	  not	  been	  adequately	  vetted	  for	  
its	  appropriateness	  in	  treating	  GBM	  or	  in	  eradicating	  BCSCs.	  We	  seek	  to	  build	  on	  
previously	  developed	  high-­‐throughput	  screening	  methods	  and	  combine	  these	  with	  
development	  of	  a	  novel	  polymeric	  drug	  delivery	  platform.	  
In	  deciding	  on	  this	  pathway,	  Occam’s	  razor	  is	  strictly	  applied:	  There	  may	  in	  fact	  be	  
one	  compound	  that	  when	  delivered	  using	  a	  novel	  polymeric	  drug	  delivery	  platform	  
substantially	  improves	  survival	  in	  GBM;	  a	  pervasive	  issue	  in	  GBM	  and	  central	  
nervous	  system	  malignancy	  therapy	  has	  been	  drug	  delivery.	  Only	  once	  we	  are	  much	  
more	  confident	  that	  the	  readily	  available	  resources	  (small	  molecule	  compounds)	  are	  
not	  active	  on	  their	  own	  should	  we	  then	  progress	  toward	  combination	  therapy	  and	  
introduction	  of	  biologics.	  Further	  the	  drawbacks	  of	  working	  with	  siRNA	  at	  this	  point	  
in	  time	  are	  clear:	  Even	  if	  we	  could	  identify	  a	  single	  gene	  which	  reliably	  decreased	  
expression	  of	  a	  critically	  important	  in	  BCSCs	  –	  and	  the	  identification	  of	  a	  single	  
“master	  switch”	  for	  all	  BCSCs	  appears	  at	  first	  blush	  just	  as	  likely	  as	  identification	  of	  a	  
small	  molecule	  compound	  which	  achieves	  the	  same	  end	  –	  issues	  of	  synthesis,	  
delivery,	  regulatory	  approval,	  and	  cost	  present	  themselves	  as	  massive	  obstacles	  
quite	  quickly.	  In	  short,	  there	  is	  no	  reason	  to	  introduce	  a	  new	  paradigm	  for	  GBM	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Hypotheses	  
	   In-­‐House	  Small	  Molecule	  Screening	  
1) In-­‐house	  screening	  will	  reveal	  previously-­‐	  or	  currently-­‐FDA-­‐approved	  
compounds	  with	  multiple	  modes	  of	  anti-­‐BCSC	  activity.	  
2) Many	  of	  the	  drugs	  with	  anti-­‐BCSC	  growth	  effect	  will	  also	  display	  the	  ability	  to	  
differentiate	  BCSCs	  that	  are	  not	  killed	  and	  impair	  the	  self-­‐renewal	  of	  BCSCs	  
as	  assessed	  by	  flow	  cytometry	  and	  neurosphere	  formation	  assay,	  
respectively.	  
	  
Combining	  Anti-­‐BCSC	  Compounds	  and	  Highly-­‐Penetrative	  Polymeric	  
Nanocarriers	  
3) We	  will	  successfully	  load	  the	  top	  candidate	  compound	  (as	  measured	  by	  
lowest	  IC50	  and	  successful	  promotion	  of	  differentiation	  and	  inhibition	  of	  
self-­‐renewal)	  into	  the	  previously	  developed	  highly-­‐penetrative	  polymeric	  
nanocarrier	  delivery	  vehicle.	  
4) Both	  highly-­‐penetrative	  polymeric	  nanocarriers	  and	  top	  candidate	  
compound	  will	  prove	  necessary	  but	  not	  sufficient	  to	  extend	  survival	  in	  rats	  
burdened	  with	  BCSC-­‐derived	  xenograft	  tumors.	  That	  is	  to	  say,	  CED	  of	  drug-­‐
only	  and	  nanocarrier-­‐only	  solutions	  will	  provide	  zero	  survival	  benefit	  while	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High-­‐Throughput	  Screening	  of	  Anti-­‐BCSC	  Small	  Molecule	  Compounds	  
5) We	  will	  develop	  a	  high-­‐throughput	  assay	  utilizing	  multiple	  diverse	  BCSC	  
lines	  that	  is	  highly	  accurate,	  highly	  reproducible,	  and	  free	  of	  systematic	  
errors	  due	  to	  plating	  and	  diffraction	  of	  light.	  
6) By	  screening	  over	  5,000	  compounds	  for	  anti-­‐BCSC	  activity,	  we	  will	  identify	  
numerous	  previously-­‐	  or	  currently-­‐approved	  drugs	  that	  inhibit	  the	  growth	  of	  
a	  genetically	  diverse	  set	  of	  BCSCs.	  
7) Compound-­‐by-­‐compound	  assessment	  will	  reveal	  certain	  shared	  chemical	  
characteristics	  of	  novel	  anti-­‐BCSC	  compounds.	  Evaluation	  of	  the	  known	  
indications	  of	  these	  drugs	  will	  generate	  new	  testable	  hypothesis	  regarding	  
both	  the	  mechanism	  of	  action	  of	  novel	  compounds	  in	  the	  setting	  of	  GBM	  and	  
the	  etiology	  and	  pathogenesis	  of	  GBM.	  
8) There	  exist	  anti-­‐BCSC	  compounds	  with	  only	  limited	  effects	  against	  normal	  
cell	  populations.	  We	  will	  identify	  candidate	  compounds	  with	  equal	  in	  vitro	  
efficacy	  as	  previously	  identified	  compound	  but	  with	  much	  more	  limited	  anti-­‐
normal	  cell	  population	  toxicity.	  
	  
Pre-­‐clinical	  Refinement	  of	  the	  Highly-­‐Penetrative	  Polymeric	  Nanocarrier	  
Platform	  for	  Magnetic	  Resonance	  Activity	  
9) We	  will	  successfully	  load	  citric	  acid-­‐coated	  superparamagnetic	  iron	  oxide	  
into	  highly-­‐penetrative	  polymeric	  nanocarriers,	  and	  doing	  so	  will	  not	  impact	  
the	  structural	  integrity	  of	  the	  nanocarriers.	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10) In	  vivo	  testing	  of	  superparamagnetic	  iron	  oxide-­‐loaded	  highly-­‐penetrative	  
polymeric	  nanocarriers	  will	  reveal	  that	  this	  formulation	  can	  be	  followed	  
long-­‐term	  by	  MRI	  and	  has	  similar	  distribution	  parameters	  as	  previously	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Specific	  Aims	  
	   In-­‐House	  Small	  Molecule	  Screening	  
1) We	  aim	  to,	  using	  low-­‐throughput	  in-­‐house	  screening	  methods,	  identify	  
candidate	  drugs	  that	  have	  been	  previously	  approved	  by	  the	  FDA	  or	  
international	  governing	  bodies	  with	  anti-­‐BCSC	  effects	  as	  measured	  by	  growth	  
inhibition.	  
2) We	  aim	  to	  characterize	  the	  in	  vitro	  effects	  of	  candidate	  drugs	  identified	  
through	  large-­‐scale	  in-­‐house	  screening	  efforts	  on	  patient-­‐derived	  glioma	  
stem	  cell	  lines,	  as	  measured	  by	  neurosphere	  formation	  inhibition	  and	  
differentiation	  status.	  
	  
Combining	  Anti-­‐BCSC	  Compounds	  and	  Highly-­‐Penetrative	  Polymeric	  
Nanocarriers	  
3) We	  aim	  to	  incorporate	  top	  candidate	  drugs	  into	  previously	  developed	  highly-­‐
penetrative	  polymeric	  nanocarriers.	  
4) We	  aim	  to	  test	  top	  candidate	  drugs	  formulated	  in	  highly-­‐penetrative	  
polymeric	  nanocarriers	  in	  vivo	  using	  a	  BCSC-­‐derived	  model.	  
5) We	  aim	  to	  develop	  a	  high-­‐throughput	  small	  molecule	  screening	  technique	  
and	  verify	  its	  accuracy	  and	  precision.	  
	  
High-­‐Throughput	  Screening	  of	  Anti-­‐BCSC	  Small	  Molecule	  Compounds	  
6) We	  aim	  to,	  using	  high-­‐throughput	  screening	  methods,	  identify	  still	  more	  
candidate	  drugs	  with	  anti-­‐BCSC	  effects	  as	  measured	  by	  growth	  inhibition.	  By	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virtue	  of	  screening	  multiple	  diverse	  BCSC	  lines,	  we	  aim	  to	  identify	  
compounds	  with	  broad-­‐based	  anti-­‐BCSC	  effects.	  
7) We	  aim	  to	  identify	  structural	  characteristics	  common	  to	  many	  candidate	  
drugs	  with	  anti-­‐BCSC	  effects.	  
8) We	  aim	  to,	  using	  a	  counter-­‐screening	  technique,	  identify	  anti-­‐BCSC	  candidate	  
drugs	  with	  limited	  effects	  against	  a	  normal	  glial	  cell	  population	  –	  thereby	  
identifying	  drugs	  which	  will	  not	  only	  be	  efficacious	  but	  safe	  for	  clinical	  
translation.	  
	  
Pre-­‐clinical	  Refinement	  of	  the	  Highly-­‐Penetrative	  Polymeric	  Nanocarrier	  
Platform	  for	  Magnetic	  Resonance	  Activity	  
9) We	  aim	  to	  prepare	  the	  highly-­‐penetrative	  polymeric	  nanocarrier	  system	  for	  
clinical	  translation	  by	  incorporation	  of	  superparamagnetic	  iron	  oxide.	  
10) We	  aim	  to	  test	  in	  vivo	  the	  stability	  and	  imaging	  properties	  of	  









	   	   	   	   	   	   	   	   	   	  




All	  chemicals,	  including	  all	  drugs	  screened	  in	  in-­‐house	  screening,	  were	  purchased	  
from	  Sigma-­‐Aldrich	  unless	  otherwise	  noted.	  Dithiazanine	  iodide	  was	  purchased	  
from	  Sigma-­‐Aldrich,	  as	  were	  ethyl	  acetate,	  dichloromethane,	  polyvinyl	  alcohol,	  




Tumor	  samples	  classified	  as	  GBM	  based	  on	  World	  Health	  Organization	  criteria	  were	  
obtained	  from	  neurosurgical	  patients	  at	  Yale-­‐New	  Haven	  Hospital	  who	  had	  
provided	  informed	  consent	  preoperatively	  (HIC	  Protocol	  #0802003495).	  BCSCs	  
were	  isolated	  in	  the	  following	  manner.	  Within	  1	  to	  3	  hrs	  of	  surgical	  removal,	  tumors	  
were	  washed,	  cut	  into	  <1	  mm3	  fragments,	  and	  enzymatically	  dissociated	  into	  single	  
cells.	  Digested	  fragments	  were	  filtered	  using	  a	  70 μm	  cell	  strainer	  (BD	  Falcon)	  and	  
collected	  in	  culture	  medium.	  The	  GS5	  cell	  line	  was	  kindly	  provided	  by	  Lamszus	  lab	  
[73].	  	  All	  primary	  tumor	  cells	  were	  collected	  and	  cultured	  in	  Neurobasal	  A	  medium	  
(Invitrogen)	  supplemented	  with	  B27	  (Invitrogen),	  fibroblast	  growth	  factor-­‐2	  
(20 ng/mL,	  Peprotech),	  and	  epidermal	  growth	  factor	  (20 ng/mL,	  Peprotech).	  
Growth	  factors	  were	  added	  at	  least	  weekly.	  Non-­‐adherent	  cells	  growing	  as	  spheres	  
were	  passaged	  as	  necessary	  and	  to	  maintain	  purity.	  All	  members	  of	  the	  Saltzman	  
lab,	  but	  most	  notably	  Professor	  Jiangbing	  Zhou	  and	  Dr	  Toral	  Patel,	  developed	  cell	  
lines	  named	  in	  the	  convention	  “PS##”.	  
	   	   	   	   	   	   	   	   	   	  




All	  BCSCs	  were	  cultured	  in	  Neurobasal	  A	  medium	  (Invitrogen;	  Carlsbad,	  CA)	  
supplemented	  with	  B27	  (Invitrogen),	  100	  ng/uL	  EGF	  (Peprotech;	  Rocky	  Hill,	  NJ),	  
100	  ng/uL	  FGF	  (Peprotech),	  and	  penicillin/streptomycin/fungizone	  (Lonza;	  
Walkersville,	  MD).	  The	  human	  glial	  cell	  line	  SVGp12	  (ATCC;	  Manassas,	  VA)	  was	  used	  
as	  a	  safety	  control.	  SVGp12	  was	  cultured	  in	  Minimal	  Essential	  Medium	  (Invitrogen)	  
supplemented	  with	  fetal	  bovine	  serum	  (Atlanta	  Biologicals;	  Lawrenceville,	  GA)	  and	  
penicillin/streptomycin/fungizone	  (Lonza).	  The	  author	  and	  all	  members	  of	  the	  
Saltzman	  group	  performed	  BCSC	  culture.	  
	  
Drug	  Compounds	  for	  Screening	  
Over	  1,000	  compounds	  were	  screened	  in-­‐house.	  This	  collection	  was	  comprised	  of	  
components	  that	  at	  one	  time	  or	  another	  were	  FDA-­‐approved.	  
Compound	  collections	  screened	  in	  high-­‐throughput	  screening	  included:	  NIH	  Clinical	  
Collection	  (NIH;	  Bethesda,	  MD),	  Pharmakon	  1600	  (Microsource;	  Gaylordsville,	  CT),	  
Ion	  Channel	  Inhibitors	  (Enzo;	  Farmingdale,	  NY),	  Kinase	  Inhibitors	  (Enzo),	  
Phosphatase	  Inhibitors	  (Enzo),	  Metabotropic	  &	  Glutamatergic	  Ligands	  (Enzo),	  and	  
FDA-­‐approved	  drugs	  (Enzo).	  The	  author,	  in	  consultation	  with	  Professor	  W	  Mark	  
Saltzman,	  Professor	  Zhou,	  and	  collaborators	  at	  the	  Yale	  Center	  for	  Molecular	  
Discovery	  selected	  all	  compound	  libraries	  for	  screening.	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Cell	  proliferation	  assays	  
For	  primary	  screening,	  a	  slightly	  modified	  MTT	  assay	  was	  used	  to	  quantify	  the	  
effects	  of	  drugs	  on	  cell	  proliferation.	  Briefly,	  cells	  were	  cultured	  in	  96-­‐well	  plates	  
(Falcon).	  6	  days	  after	  treatment,	  media	  was	  removed	  and	  replaced	  with	  fresh	  media	  
containing	  10%	  MTT	  (3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐diphenyl	  tetrazolium	  
bromide)	  (Sigma)	  solution	  (4.14	  mg/mL).	  Four	  hours	  after	  incubation	  at	  37ºC,	  all	  
media	  was	  removed.	  Formazan	  was	  dissolved	  in	  DMSO	  and	  the	  optical	  density	  
(O.D.)	  was	  measured	  at	  590	  nm.	  The	  relative	  inhibition	  on	  growth	  was	  determined	  
using	  the	  following	  formula:	  
	  
𝐺𝑟𝑜𝑤𝑡ℎ  𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =   




Proliferation	  was	  also	  assessed	  and	  IC50	  calculated	  using	  AlamarBlue	  (Invitrogen)	  
fluorescence.	  Briefly,	  cells	  were	  plated	  at	  subconfluent	  concentration	  in	  black	  clear-­‐
bottomed	  96-­‐well	  plates	  (Falcon)	  with	  drug	  concentrations	  spanning	  eight	  orders	  of	  
magnitude.	  Three	  days	  post-­‐plating,	  AlamarBlue	  was	  added	  at	  manufacturer’s	  
recommended	  concentration.	  Cells	  were	  incubated	  at	  37ºC	  for	  200	  min	  and	  
quantified	  (ex:	  544	  nm,	  em:	  590	  nm).	  Fluorescence	  measures	  were	  corrected	  for	  
background	  media	  and	  drug	  fluorescence	  and	  normalized	  to	  the	  mean	  of	  vehicle	  
measures.	  IC50	  values	  were	  determined	  using	  four-­‐parameter	  logistic	  modeling	  
using	  normalized	  point	  estimates.	  The	  author	  and	  Professor	  Zhou	  performed	  all	  cell	  
proliferation	  assays.	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Spheroid	  formation	  assay	  
BCSCs	  were	  plated	  as	  single-­‐cell	  suspensions	  of	  5	  cells	  per	  μL	  in	  48-­‐well	  plates	  
(Falcon).	  Cells	  were	  treated	  with	  1	  μM	  drug	  or	  equivalent	  concentration	  of	  DMSO.	  
Growth	  factor	  was	  supplemented	  on	  day	  5.	  Wells	  were	  counted	  on	  day	  7.	  Colonies	  






The	  author	  performed	  all	  spheroid	  formation	  assays.	  
	  
Flow	  cytometry	  
BCSCs	  were	  plated	  as	  single-­‐cell	  suspensions	  in	  6-­‐well	  plates	  with	  100	  nM	  drug	  or	  
DMSO.	  3	  days	  after	  plating,	  suspensions	  were	  collected	  and	  flow	  cytometry	  
performed.	  Briefly,	  following	  reconstitution	  in	  0.5%	  BSA	  in	  PBS	  (w/v),	  dissociated	  
cells	  were	  washed	  in	  cold	  PBS	  and	  subsequently	  incubated	  with	  biotin-­‐conjugated	  
anti-­‐CD133	  (PROM1)	  antibody	  (Miltenyi	  Biosciences).	  Suspensions	  were	  incubated	  
with	  avidin-­‐conjugated	  AlexaFluor	  488	  (Invitrogen)	  and	  read	  on	  a	  BD	  FACSCAN	  flow	  
cytometer	  (BD	  Biosciences).	  Geometric	  means	  were	  calculated	  in	  FlowJo	  (TreeStar,	  
Inc.),	  corrected	  for	  background	  (secondary	  only),	  and	  normalized	  to	  DMSO-­‐only	  
treated	  cells.	  The	  author	  performed	  all	  flow	  cytometry	  studies.	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Ultrasmall	  Nanoparticle	  Synthesis	  (Figure	  1)	  
Nanoparticles	  loaded	  with	  dithiazanine	  iodide	  were	  synthesized	  by	  a	  single-­‐
emulsion	  solvent	  evaporation	  technique.	  100	  mg	  poly-­‐lactic-­‐co-­‐glycolic	  acid	  (50:50,	  
Polysciences	  and	  Birmingham)	  and	  agents	  to	  be	  encapsulated	  were	  dissolved	  in	  2	  
mL	  dichloromethane	  or	  ethyl	  acetate.	  	  The	  polymer/drug	  solution	  was	  then	  added	  
dropwise	  to	  4	  mL	  2.5%	  polyvinyl	  alcohol	  as	  the	  outer	  aqueous	  phase	  and	  sonicated	  
to	  form	  an	  emulsion.	  The	  emulsion	  was	  poured	  into	  a	  beaker	  containing	  aqueous	  
0.3%	  (v/v)	  polyvinyl	  alcohol	  and	  stirred	  at	  room	  temperature	  for	  3	  hours	  
(dichloromethane	  as	  solvent)	  or	  5	  hours	  (ethyl	  acetate	  as	  solvent)	  to	  allow	  solvent	  
to	  evaporate	  and	  particles	  to	  harden.	  
To	  synthesize	  standard-­‐sized	  nanoparticles,	  following	  the	  solvent	  evaporation	  
phase,	  the	  nanoparticle	  solution	  was	  subjected	  to	  typical	  centrifugation	  speeds	  
(11,500	  x	  g	  for	  15	  minutes,	  x	  3)	  and	  the	  pellet	  was	  collected.	  To	  synthesize	  
ultrasmall	  nanoparticles,	  following	  the	  solvent	  evaporation	  phase,	  the	  nanoparticle	  
solution	  was	  first	  centrifuged	  at	  low	  speed	  (8,000	  x	  g	  for	  10	  minutes)	  to	  pellet	  the	  
large	  particles.	  	  Supernatant	  was	  decanted	  and	  ultrasmall	  nanoparticles	  were	  
collected	  through	  high-­‐speed	  ultracentrifugation	  (100,000	  x	  g	  for	  30	  minutes,	  x	  2).	  
To	  prevent	  nanoparticle	  aggregation	  during	  lyophilization,	  trehalose	  was	  added	  to	  
the	  final	  aqueous	  solution	  at	  a	  ratio	  of	  0.5:1	  (trehalose:nanoparticles)	  by	  mass	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Antitumor	  activity	  in	  xenograft	  model	  
To	  establish	  tumors	  for	  evaluation	  of	  paclitaxel-­‐loaded	  PLGA	  nanoparticles,	  nude	  
rats	  were	  first	  anesthetized	  with	  a	  ketamine/xylazine	  mixture.	  	  Animals	  were	  then	  
prepped	  with	  betadine	  and	  alcohol	  and	  placed	  in	  a	  stereotactic	  frame.	  	  A	  linear	  
midline	  incision	  was	  made	  and	  a	  1.5	  mm	  diameter	  hole	  was	  drilled	  in	  the	  skull	  3mm	  
lateral	  and	  0.5	  mm	  anterior	  to	  bregma.	  	  A	  26G	  Hamilton	  syringe	  was	  inserted	  to	  a	  
depth	  of	  5mm.	  	  The	  tissue	  was	  allowed	  to	  equilibrate	  mechanically	  for	  2	  minutes.	  	  
Subsequently,	  5x105	  GS5	  cells	  in	  2	  μL	  PBS	  were	  injected	  into	  the	  brain	  over	  10	  
minutes.	  	  The	  burr	  hole	  was	  filled	  with	  bone	  wax	  (Lukens,	  Reading	  PA),	  the	  scalp	  
closed	  with	  surgical	  staples,	  and	  the	  rat	  removed	  to	  a	  clean	  cage	  with	  free	  access	  to	  
food	  and	  water	  mixed	  with	  ibuprofen.	  Treatments	  were	  performed	  10	  days	  
following	  tumor	  inoculation.	  Rats	  were	  again	  anesthetized,	  prepped,	  and	  placed	  in	  a	  
stereotactic	  frame.	  	  The	  wound	  was	  reopened	  and	  the	  Hamilton	  syringe	  was	  
oriented	  as	  described	  previously.	  20	  μL	  of	  either	  nanoparticles	  (100	  mg/mL)	  or	  free	  
drug	  (either	  60	  μg	  or	  120	  μg)	  were	  infused	  continuously	  at	  a	  rate	  of	  0.667μL/min.	  	  
Equilibration	  was	  performed	  and	  animals	  were	  handled	  post-­‐operatively	  as	  
described.	  The	  animals'	  weight,	  grooming,	  and	  general	  health	  were	  monitored	  on	  a	  
daily	  basis.	  	  Animals	  were	  euthanized	  after	  either	  a	  15%	  loss	  in	  body	  weight	  or	  
when	  it	  was	  humanely	  necessary	  due	  to	  clinical	  symptoms.	  Professor	  Zhou	  and	  Dr	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High-­‐Throughput	  Screening	  of	  BCSCs	  (Figure	  2)	  
In	  collaboration	  with	  the	  Yale	  Center	  for	  Molecular	  Discovery,	  we	  optimized	  a	  
fluorescence-­‐based	  high-­‐throughput	  assay	  for	  identification	  of	  anti-­‐BCSC	  
compounds.	  We	  performed	  primary	  screening	  of	  ~5,000	  compounds	  of	  varying	  
origins	  (kinase/phosphatase	  inhibitors,	  internationally-­‐approved	  compounds,	  FDA-­‐
approved	  compounds,	  etc.)	  for	  anti-­‐BCSC	  growth	  activity.	  Briefly,	  assays	  were	  
performed	  in	  384-­‐well	  black	  plates.	  GS5,	  PS16,	  and	  PS30	  cells	  were	  cultured	  in	  the	  
manner	  described	  previously	  in	  T150	  flasks.	  Cells	  were	  seeded	  in	  384-­‐well	  black-­‐
well,	  clear-­‐bottom	  plates	  at	  a	  density	  of	  2,000	  cells	  per	  well	  either	  by	  multichannel	  
pipette	  or	  multidrop	  (Thermo	  Scientific)	  in	  total	  volume.	  24	  hours	  later,	  compound	  
was	  added	  to	  a	  concentration	  of	  8	  μM	  using	  a	  sterilized	  PlateMatePlus	  transfer	  
apparatus	  (Matrix	  Technologies).	  Following	  3	  day	  incubation	  at	  37C,	  cell	  viability	  
was	  determined	  using	  the	  mitochondrial	  redox	  assay	  AlamarBlue	  (Invitrogen)	  as	  
above.	  Fluorescence	  intensity	  (λex	  =	  544	  nm;	  λem	  =	  590	  nm)	  was	  determined	  using	  
an	  Envision	  plate	  reader	  (PerkinElmer).	  
Compounds	  were	  rank-­‐ordered	  according	  to	  their	  percent	  mortality	  effect	  on	  the	  
various	  BCSC	  lines.	  The	  top	  100	  compounds	  were	  identified	  and	  subsequently	  
screened	  against	  the	  normal	  human	  glial	  cell	  line	  SVGp12	  using	  similar	  conditions	  as	  
the	  primary	  screen.	  The	  author,	  in	  collaboration	  with	  the	  Yale	  Center	  for	  Molecular	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Synthesis	  of	  superparamagnetic	  iron	  oxide	  
Superparamagnetic	  iron	  oxide	  (SPIO)	  synthesis	  and	  coating	  with	  oleic	  acid,	  
oleylamine,	  and	  1,2-­‐hexadecanediol	  proceeded	  according	  to	  Ragheb	  et	  al,	  2013	  [74].	  
Black	  solution	  was	  precipitated	  in	  100%	  ethanol,	  washed	  twice,	  and	  dried	  to	  form	  a	  
black	  powder.	  Professor	  Zhou	  performed	  SPIO	  synthesis.	  
	  
Encapsulation	  of	  superparamagnetic	  iron	  oxide	  in	  highly-­‐penetrative	  
polymeric	  nanocarriers	  
Reaction	  conditions	  for	  highly-­‐penetrative	  polymeric	  nanocarrier	  synthesis	  were	  
the	  same	  as	  described	  above.	  Superparamagnetic	  iron	  oxide	  prepared	  as	  above	  was	  
added	  to	  single	  emulsion	  reaction	  mixture	  along	  with	  coumarin-­‐6	  in	  ethyl	  acetate	  to	  
final	  concentrations	  ranging	  from	  0.25mg/20μL	  to	  2mg/20μL.	  The	  
polymer/superparamagnetic	  iron	  oxide	  solution	  was	  then	  added	  dropwise	  to	  4	  mL	  
of	  2.5%	  polyvinyl	  alcohol	  as	  the	  outer	  aqueous	  phase	  and	  sonicated	  to	  form	  an	  
emulsion.	  The	  emulsion	  was	  poured	  into	  a	  beaker	  containing	  aqueous	  0.3%	  (v/v)	  
polyvinyl	  alcohol	  and	  stirred	  at	  room	  temperature	  for	  3	  hours	  (dichloromethane	  as	  
solvent)	  or	  5	  hours	  (ethyl	  acetate	  as	  solvent)	  to	  allow	  the	  solvent	  to	  evaporate	  and	  
the	  particles	  to	  harden.	  
To	  synthesize	  ultrasmall	  nanoparticles,	  following	  the	  solvent	  evaporation	  phase,	  the	  
nanoparticle	  solution	  was	  first	  subjected	  to	  low-­‐speed	  centrifugation	  (8,000	  x	  g	  for	  
10	  minutes)	  to	  pellet	  and	  remove	  the	  large	  particles.	  	  The	  ultrasmall	  nanoparticles	  
remaining	  in	  the	  supernatant	  were	  subsequently	  collected	  through	  high-­‐speed	  
ultracentrifugation	  (100,000	  g	  for	  30	  minutes,	  x	  2).	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To	  prevent	  nanoparticle	  aggregation	  during	  lyophilization,	  trehalose	  was	  added	  to	  
the	  final	  aqueous	  solution	  at	  a	  ratio	  of	  0.5:1	  (trehalose:nanoparticles)	  by	  mass	  
immediately	  prior	  to	  lyophilization.	  
Nanoparticles	  were	  injected	  into	  rat	  brain	  parenchyma	  using	  CED	  as	  described	  in	  
the	  section	  Antitumor	  activity	  in	  xenograft	  model.	  The	  author,	  Professor	  Zhou,	  
neurosurgery	  resident	  Dr	  Komli-­‐Kofi	  Atsina,	  and	  the	  Diagnostic	  Radiology	  team	  of	  
Dr	  Peter	  Herman	  and	  Dr	  Daniel	  Coman	  performed	  these	  studies.	  
	  
MRI	  of	  rats	  injected	  with	  superparamagnetic	  iron	  oxide-­‐loaded	  highly-­‐
penetrative	  polymeric	  nanocarriers	  
In	  collaboration	  with	  MRI	  Research	  Center,	  rats	  were	  anesthetized	  using	  isoflurane	  
and	  loaded	  into	  9.2T	  small	  animal	  MRI.	  A	  second	  set	  of	  experiments	  was	  performed	  
in	  a	  4T	  small	  animal	  MRI.	  Sixteen	  coronal	  images	  were	  collected	  for	  each	  rat	  using	  
proprietary	  software.	  Vitals	  were	  monitored	  throughout	  imaging.	  The	  Diagnostic	  
Radiology	  team	  of	  Dr	  Peter	  Herman	  and	  Dr	  Daniel	  Coman	  performed	  these	  studies	  
with	  the	  author’s	  assistance.	  
	  
Statistical	  analysis	  of	  High-­‐Throughput	  Screen	  
All	  data	  were	  taken	  in	  triplicate	  and	  reported	  as	  mean	  and	  standard	  deviation.	  
Comparison	  of	  two	  conditions	  was	  evaluated	  by	  a	  paired	  Student’s	  t-­‐test.	  	  Kaplan-­‐
Meier	  analysis	  was	  employed	  to	  evaluate	  the	  effect	  of	  various	  treatments	  on	  
survival.	  	  A	  p	  ≤	  0.05	  was	  considered	  to	  indicate	  a	  statistically	  significant	  difference.	  
Initial	  quality	  control	  analysis	  of	  high-­‐throughput	  screening	  data	  was	  performed	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using	  Z’-­‐factor	  statistic,	  a	  reliable	  measure	  of	  the	  difference	  between	  true	  positive	  
and	  true	  negative	  controls	  [75].	  Z’-­‐factor	  is	  calculated	  according	  to	  the	  formula:	  
	  
where	  E	  refers	  to	  positive	  control	  samples	  (the	  previously	  identified	  compound	  
anisomycin),	  S	  refers	  to	  negative	  control	  samples	  (in	  our	  case,	  the	  vehicle	  control	  
DMSO),	  σ	  refers	  to	  standard	  deviation,	  and	  𝑦	  refers	  to	  mean	  fluorescence	  signal.	  Z’	  is	  
interpreted	  as	  1	  being	  ideal,	  >1	  being	  impossible,	  0.5-­‐1	  being	  an	  excellent	  assay,	  
0.25-­‐0.5	  as	  being	  a	  good	  and	  acceptable	  assay,	  <0.25	  as	  being	  a	  marginal	  to	  poor	  and	  














Figure 2: A possible 16⇥24 plate design with uniformly spaced controls. Each square corresponds
to a well. Well devoted to controls are indicated with darker color.
a particular screen. At an even more basic level, the first step in the analysis of HTS data has
to consists in the evaluation of the success of the experiment corresponding to each plate. While
the automation and standardization of the process has increased, it is still important to consider
that some plates may not lead to valuable signals. This is especially true in secondary screenings,
where smaller cell amounts are used, more hands-on intervention is required, and there is generally
a higher variability across plates. Figure 4,for example, illustrates one example of ‘failed’ plate in
the secondary screen we analyzed.
We are interested in the values y
i
from one plate (p
i
= p), and hence reflecting one cell line
`
i
= ` and obviously one batch b
i
= b. To evaluate the presence of biologically meaningful signal
in the overall reads from plate p, one relies especially on the signal y
i
relative to compounds of
known effect. For example, the mentioned Z 0 has the following form:













In the screens we analyzed, only neutral controls were used, making the use of such statistics
impractical. However, information can be gathered by the comparison of the reads from neutral
controls {i : k
i
= N} := N and the est of the data {i : k
i
6= N} := E . We can assume that
7
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Results	  
Identification	  of	  novel	  small	  molecules	  that	  inhibit	  BCSC	  proliferation	  and	  self-­‐
renewal	  
Tumor	  cell	  heterogeneity	  and	  resistance	  are	  significant	  obstacles	  that	  must	  be	  
overcome	  to	  cure	  GBM	  –	  BCSCs	  must	  be	  eliminated.	  Given	  that	  BCSCs	  are	  known	  to	  
resist	  standard	  chemotherapy	  drugs,	  including	  paclitaxel,	  novel	  small	  molecules	  that	  
inhibit	  the	  growth	  of	  BCSCs	  must	  be	  identified	  (Fig.	  3a).	  We	  therefore	  screened	  a	  
library	  of	  ~2,000	  compounds	  that	  at	  one	  time	  or	  another	  have	  been	  approved	  for	  
use	  in	  humans	  by	  the	  FDA	  for	  growth-­‐inhibitory	  activity	  against	  GS5.	  Briefly,	  GS5	  
cells	  were	  plated	  in	  96-­‐well	  format,	  treated	  with	  5	  μM	  drug,	  and	  evaluated	  for	  
viability	  three	  days	  later	  using	  MTT.	  Initial	  hits	  were	  subsequently	  evaluated	  for	  
inhibition	  of	  GS5	  sphere	  formation,	  a	  measure	  of	  BCSC	  self-­‐renewal.	  Selection	  
criteria	  included	  both	  growth	  inhibition	  and	  sphere	  formation	  inhibition	  of	  ≥	  50%	  
(Fig.	  3a).	  
Thirty-­‐two	  candidate	  compounds	  were	  identified	  (Table	  2),	  only	  3	  of	  which	  were	  
confirmed	  in	  a	  high-­‐throughput	  screen	  in	  BCSCs	  (Visneyi	  ref).	  The	  BCSC	  growth-­‐
inhibitory	  activity	  of	  many	  compounds	  was	  confirmed	  using	  AlamarBlue.	  One	  
compound	  in	  particular,	  the	  anti-­‐helminthic	  cyanine	  dye	  dithiazanine	  iodide,	  
potently	  inhibited	  GS5	  proliferation	  with	  an	  IC50	  of	  79	  nM.	  Dithiazanine	  iodide	  
inhibited	  GS5	  sphere	  formation,	  a	  measurement	  of	  BCSC	  self-­‐renewal,	  by	  93.6%.	  
Additionally,	  dithiazanine	  iodide	  decreased	  the	  CD133+	  cell	  population	  by	  56.6%	  in	  
treated	  cultures.	  Dithiazanine	  was	  also	  evaluated	  in	  two	  additional	  BCSC	  lines	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isolated	  in	  our	  lab,	  PS11	  and	  PS16,	  and	  showed	  similar	  anti-­‐BCSC	  effects	  in	  both	  (Fig	  
3b).	  
Follow-­‐up	  studies	  of	  other	  top	  candidate	  compounds,	  including	  emetine	  (the	  top-­‐
ranked	  compound	  from	  UCLA	  screen),	  acriflavine,	  and	  digoxin,	  indicate	  limited	  
growth	  inhibitory	  effects	  against	  BCSCs	  and	  bulk	  tumor	  cells	  in	  normal	  oxygen	  
atmosphere	  and	  BCSCs	  under	  hypoxic	  conditions	  (Table	  3)	  with	  high	  potency	  (Table	  
4).	  As	  expected,	  emetine	  showed	  high	  efficacy	  and	  potency	  under	  all	  conditions,	  in	  
line	  with	  previously	  reported	  data	  from	  Visnyei,	  et	  al.	  Notably,	  emetine	  and	  digoxin	  
were	  routinely	  at	  least	  twice	  as	  potent	  as	  acriflavine.	  Routinely,	  digoxin	  displayed	  
lower	  efficacy	  than	  acriflavine	  and	  emetine,	  suggesting	  that	  even	  if	  high	  levels	  of	  
drug	  could	  be	  delivered	  to	  the	  site	  of	  the	  tumor,	  only	  minimal	  BCSC	  killing	  would	  
occur.	  Additionally,	  the	  lone	  bulk	  tumor	  cell	  line	  used,	  U87,	  showed	  profound	  
resistance	  to	  digoxin,	  suggesting	  that	  if	  this	  drug	  were	  to	  be	  used	  as	  a	  
chemotherapeutic	  for	  GBM,	  it	  would	  need	  to	  be	  combined	  with	  a	  known	  bulk	  tumor	  
cell-­‐inhibiting	  agent	  such	  as	  BCNU,	  PCV,	  or	  temozolomide.	  
	  
CED	  of	  ultrasmall,	  dithiazanine	  iodide-­‐loaded	  PLGA	  nanoparticles	  for	  GBM	  
therapy	  
Toward	  development	  of	  an	  efficacious,	  translatable	  therapy	  for	  GBM,	  we	  sought	  to	  
assess	  whether	  CED	  of	  ultrasmall,	  DI-­‐loaded	  nanoparticles	  could	  prevent	  the	  growth	  
of	  BCSC-­‐derived	  xenografts.	  Since	  the	  ultrasmall	  nanoparticles	  can	  penetrate	  over	  a	  
large	  volume	  of	  brain	  parenchyma,	  we	  hypothesized	  that	  CED	  of	  ultrasmall,	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dithiazanine	  iodide-­‐loaded	  nanoparticles	  would	  have	  an	  unprecedented	  advantage	  
in	  treating	  these	  disseminated	  tumors.	  
To	  evaluate	  their	  efficacy	  in	  vivo,	  ultrasmall,	  dithiazanine	  iodide-­‐loaded	  
nanoparticles	  were	  administrated	  into	  rat	  brains	  bearing	  tumors	  derived	  from	  GS5	  
using	  the	  same	  procedures	  described	  previously.	  As	  shown	  in	  figure	  4,	  DI	  
nanoparticles	  significantly	  increased	  survival	  of	  tumor-­‐bearing	  rats;	  these	  rats	  have	  
been	  alive	  for	  over	  nine	  months.	  Professor	  Zhou	  and	  Dr	  Patel	  carried	  out	  these	  
studies.	  
	  
High-­‐throughput	  screening	  assay:	  Quality	  control	  
There	  are	  three	  characteristics	  of	  high	  quality	  high-­‐throughput	  assays:	  the	  ability	  to	  
distinguish	  positive	  and	  negative	  results	  and	  be	  relatively	  free	  of	  systematic	  errors	  
such	  as	  row	  and	  column	  effects.	  The	  high-­‐throughput	  assay	  as	  constructed	  has	  
strong	  Z’	  scores	  (Fig.	  5e),	  a	  statistical	  measure	  of	  the	  difference	  between	  positive	  
and	  negative	  results.	  Z’	  score	  greater	  than	  0.5	  is	  considered	  excellent	  and	  is	  industry	  
standard	  –	  it	  is	  interpreted	  as	  being	  a	  12	  standard	  deviation	  difference	  between	  true	  
positive	  and	  true	  negative	  controls.	  Distinguishing	  row	  and	  column	  effects	  is	  purely	  
observational,	  and	  no	  clear	  industry	  standard	  exists	  for	  statistical	  evaluation.	  
Compared	  to	  previously	  developed	  assays	  [76]	  our	  assay	  displays	  less	  variability	  
when	  binned	  rows	  of	  384-­‐well	  plates	  (Fig.	  6a-­‐c).	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High-­‐throughput	  screening	  assay:	  Identification	  of	  Candidate	  Anti-­‐BCSC	  
Compounds	  
Using	  a	  fluorescence-­‐based	  methodology,	  cell	  growth	  inhibitory	  effects	  of	  
compounds	  were	  assessed.	  Compounds	  with	  anti-­‐growth	  activity	  against	  one	  BCSC	  
line	  tended	  to	  be	  highly	  efficacious	  in	  other	  BCSC	  lines	  (Fig.	  7a).	  That	  is	  to	  say,	  if	  a	  
compound	  were	  efficacious	  against	  one	  cell	  line,	  it	  was	  likely	  efficacious	  against	  all	  
cell	  lines.	  Further	  investigation	  of	  signal	  inhibition	  showed	  that	  over	  200	  
compounds	  had	  greater	  than	  50%	  cell	  growth	  inhibitory	  power	  in	  at	  least	  one	  BCSC	  
line	  (Fig.	  7b).	  PS16	  cells	  appeared	  the	  most	  sensitive	  to	  tested	  drugs,	  with	  PS30	  and	  
GS5	  being	  substantially	  less	  so.	  Ninety-­‐nine	  compounds	  with	  greater	  than	  50%	  
inhibitory	  effect	  against	  all	  BCSC	  lines	  were	  identified	  (Fig.	  7b).	  Compared	  to	  
previously	  published	  exploratory	  small	  molecule	  screens,	  the	  percentage	  of	  
compounds	  with	  anti-­‐growth	  efficacy	  is	  high,	  largely	  owing	  to	  the	  fact	  that	  our	  
libraries	  are	  biased	  toward	  inclusion	  of	  anti-­‐growth	  drugs.	  For	  follow-­‐up	  
experimental	  convenience,	  compounds	  were	  ranked	  according	  to	  their	  mean	  anti-­‐
growth	  efficacy	  across	  the	  three	  cell	  lines.	  Three	  hundred	  twenty	  compounds	  were	  
selected	  for	  repeat	  screening	  in	  BCSCs	  and	  counter-­‐screening	  against	  normal	  glial	  
cells	  SVGp12	  (Fig.	  7c).	  
	  
High-­‐throughput	  screening	  assay:	  Counter-­‐screening	  of	  candidate	  compounds	  
for	  glial	  cell	  toxicity	  
As	  discussed	  previously,	  our	  earlier	  low-­‐throughput	  screening	  efforts	  identified	  
dithiazanine	  iodide	  as	  a	  strong	  candidate	  anti-­‐BCSC	  drug.	  One	  issue	  with	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dithiazanine	  iodide,	  however,	  is	  its	  history	  of	  systemic	  toxicities	  [77].	  Furthermore,	  
in-­‐house	  evaluation	  of	  dithiazanine	  iodide	  showed	  toxicity	  against	  the	  normal	  glial	  
cell	  line	  SVGp12	  (Fig.	  8a).	  Dithiazanine	  iodide	  displays	  high	  activity,	  with	  nanomolar	  
IC50,	  and	  near	  100%	  efficacy	  at	  micromolar	  doses.	  In	  the	  interests	  of	  finding	  a	  
compound	  with	  anti-­‐BCSC	  efficacy	  but	  without	  toxicity	  against	  SVGp12,	  the	  top	  320	  
compounds	  from	  primary	  screening	  were	  “counter-­‐screened”	  against	  SVGp12	  in	  
duplicate	  with	  the	  goal	  of	  identifying	  safe,	  efficacious	  compounds	  for	  GBM	  
treatment.	  
Anti-­‐BCSC	  and	  anti-­‐glial	  cell	  data	  were	  collected	  and	  expressed	  as	  efficacy.	  
Instructive	  for	  data	  viewing	  is	  to	  plot	  the	  anti-­‐glial	  “efficacy”	  for	  a	  given	  compound	  
versus	  its	  mean	  anti-­‐BCSC	  efficacy	  (Fig.	  8b).	  Twelve	  compounds	  were	  found	  to	  have	  
anti-­‐BCSC	  efficacy	  greater	  than	  dithiazanine	  iodide,	  and	  49	  compounds	  had	  greater	  
anti-­‐BCSC	  efficacy	  than	  our	  previously	  identified	  positive	  control	  anisomycin	  (Table	  
5,	  red	  diamonds	  in	  Fig.	  8b).	  Five	  of	  the	  twelve	  compounds	  had	  substantially	  less	  
anti-­‐glial	  cell	  toxicity:	  mitoxantrone,	  emetine,	  quinacrine,	  pyrithione,	  benzalkonium	  
chloride,	  and	  benzethonium	  chloride.	  
Side-­‐by-­‐side	  comparison	  for	  a	  given	  drug	  of	  anti-­‐BCSC	  anti-­‐glial	  cell	  efficacy	  displays	  
the	  differences	  well	  (Fig.	  8c).	  Increased	  difference	  between	  the	  two	  efficacy	  values	  
indicates	  a	  relative	  preference	  for	  efficacy	  against	  one	  cell	  type.	  This	  graph	  makes	  
clear	  that	  we	  have	  identified	  compounds	  with	  in	  vitro	  anti-­‐BCSC	  efficacy	  as	  high	  as	  
the	  best	  previously	  identified	  (and	  in	  vivo-­‐confirmed)	  small	  molecule	  drug	  but	  with	  
less	  anti-­‐glial	  cell	  toxicity.	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In	  vivo	  MRI	  of	  superparamagnetic	  iron	  oxide-­‐loaded	  nanoparticles	  
Following	  loading	  of	  superparamagnetic	  iron	  oxide	  into	  highly-­‐penetrative	  
polymeric	  nanocarriers,	  CED	  of	  nanoparticles	  in	  normal	  rat	  brain	  was	  performed	  
using	  methods	  described	  above.	  Varying	  doses	  of	  superparamagnetic	  iron	  oxide	  
were	  utilized	  in	  these	  experiments,	  ranging	  from	  0.25mg/20μL	  to	  2mg/20μL.	  Early	  
experiments	  using	  high-­‐concentration	  SPIO	  (2mg/20μL)	  were	  successful	  insofar	  as	  
contrast	  signal	  remaining	  in	  brain	  parenchyma	  for	  one	  month.	  The	  weakness	  of	  high	  
dose-­‐SPIO	  was	  that	  intensities	  recorded	  immediately	  post-­‐infusion	  were	  beyond	  the	  
upper	  limit	  of	  detection	  (“blown	  out”	  or	  “saturated”).	  An	  eight-­‐fold	  reduction	  in	  
SPIO	  concentration	  to	  0.25mg/20μL	  produced	  T2	  MRI	  signal	  that	  remained	  for	  one	  
month	  (Fig.	  9c-­‐d)	  and	  but	  was	  saturated	  on	  initial	  imaging	  (Fig.	  9a-­‐b).	  
Initial	  observation	  suggested	  that	  a	  pocket	  of	  non-­‐nanoparticle-­‐containing	  infusate	  
had	  collected,	  and	  prior	  experience	  suggested	  this	  was	  secondary	  to	  the	  20μL	  
volume	  used.	  To	  estimate	  the	  effect	  of	  infusate	  volume	  on	  short-­‐	  and	  long-­‐term	  
signal,	  one	  rat	  was	  infused	  with	  an	  equal	  concentration	  of	  SPIO	  albeit	  in	  a	  10μL	  
volume.	  Initial	  imaging	  results	  showed	  that	  a	  decrease	  in	  non-­‐signal	  bubble	  (Fig.	  9f).	  
As	  expected,	  at	  time	  of	  infusion,	  MR	  signal	  intensity	  was	  not	  saturated	  (Fig.	  9g-­‐h),	  
and	  the	  contrast	  signal	  was	  present	  for	  up	  to	  one	  month	  (Fig.	  9i-­‐j).	  
While	  not	  measured	  directly,	  we	  expect	  premature	  release	  of	  gadolinium	  to	  play	  
only	  a	  minor	  role	  in	  these	  results,	  as	  the	  half-­‐life	  of	  gadolinium	  in	  cerebrospinal	  fluid	  
has	  been	  previously	  reported	  as	  approximately	  between	  8.5	  hours	  in	  stroke	  studies,	  
albeit	  with	  a	  different	  formulation	  [78].	  Modified	  superparamagnetic	  iron	  oxide	  (e.g.	  
with	  dextran	  coating)	  tends	  to	  have	  longer	  plasma	  half-­‐life	  (on	  the	  order	  of	  14-­‐30	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hours)	  due	  to	  slower	  opsonization	  and	  clearance	  from	  the	  blood	  pool	  [57].	  Together,	  
these	  data	  show	  that	  superparamagnetic	  iron	  oxide	  can	  be	  loaded	  into	  highly-­‐
penetrative	  polymeric	  nanocarriers	  without	  affecting	  morphologic	  characteristics	  
and	  distribution	  properties	  and	  can	  be	  followed	  using	  T2	  MRI	  over	  at	  least	  a	  month-­‐
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Discussion	  
In	  this	  thesis,	  I	  explain	  in	  detail	  one-­‐half	  of	  the	  development	  of	  a	  potential	  
therapeutic	  for	  the	  treatment	  of	  GBM.	  Overall,	  this	  novel	  therapeutic	  addresses	  the	  
two	  most	  commonly	  cited	  obstacles	  to	  effective	  therapy:	  1)	  the	  infiltrative	  nature	  of	  
GBM	  tumors	  and	  2)	  the	  genetic	  heterogeneity	  of	  the	  tumor	  and	  chemoresistance	  of	  
BCSCs,	  which	  give	  rise	  to	  drug	  delivery	  and	  discovery	  challenges,	  respectively.	  
Additionally,	  I	  discuss	  further	  the	  impact	  of	  high-­‐throughput	  screening	  against	  
multiple	  genetically	  diverse	  BCSC	  lines,	  the	  role	  of	  counter-­‐screening	  against	  a	  
normal	  cell	  population,	  and	  the	  development	  of	  a	  MR-­‐compatible	  delivery	  vehicle.	  
Altogether,	  I	  will	  show	  the	  clinical	  readiness	  of	  this	  new	  and	  exciting	  therapeutic	  
modality.	  
	  
Impact	  of	  the	  highly-­‐penetrative	  polymeric	  nanocarrier	  delivery	  vehicle	  
To	  overcome	  the	  challenges	  associated	  with	  drug	  delivery,	  we	  developed	  a	  
controlled-­‐release	  delivery	  system	  comprised	  of	  ultrasmall	  poly-­‐lactic-­‐co-­‐glycolic	  
acid	  nanoparticles	  that	  can	  penetrate	  substantially	  (~	  7-­‐fold)	  higher	  volumes	  than	  
conventional	  poly-­‐lactic-­‐co-­‐glycolic	  acid	  nanoparticles	  when	  delivered	  intracranially	  
using	  CED.	  	  It	  was	  also	  encouraging	  to	  note	  that	  the	  Vd/Vi	  achieved	  in	  rodent	  studies	  
were	  comparable	  to	  those	  achieved	  with	  nanoliposomal	  delivery	  systems	  [79].	  
Highly-­‐penetrative	  polymeric	  nanocarriers	  delivered	  in	  pig	  brains	  using	  CED	  
penetrated	  into	  volumes	  of	  approximately	  1179	  mm3.	  	  Since	  the	  vast	  majority	  of	  
GBM	  tumors	  recur	  within	  2	  cm	  of	  the	  original	  tumor	  focus	  [12],	  the	  penetrative	  
	   	   	   	   	   	   	   	   	   	  
	   	  
44
capacity	  of	  these	  ultrasmall	  nanoparticles	  delivered	  by	  CED	  may	  sufficiently	  address	  
the	  infiltrative	  nature	  of	  GBM	  in	  future	  clinical	  application.	  
In	  comparison	  to	  currently	  available	  nanocarrier	  drug	  delivery	  systems,	  this	  
platform	  has	  at	  least	  three	  clear	  advantages.	  	  First,	  the	  polymer	  has	  an	  excellent	  
safety	  profile:	  poly-­‐lactic-­‐co-­‐glycolic	  acid	  was	  approved	  by	  the	  Food	  and	  Drug	  
Administration	  (FDA)	  in	  1969	  and	  has	  safely	  been	  used	  in	  clinics	  since	  that	  time.	  
Second,	  the	  release	  kinetics	  of	  these	  nanoparticles	  can	  be	  more	  easily	  modulated	  
than	  those	  of	  competing	  nanocarrier	  systems	  utilized	  in	  intracranial	  applications,	  
namely	  liposomes	  and	  micelles.	  Third,	  the	  versatile	  surface	  modification	  approach	  
described	  previously	  enables	  rapid,	  modular	  attachment	  of	  biotinylated	  agents,	  
thereby	  allowing	  for	  efficient	  labeling	  of	  nanoparticles	  with	  a	  host	  of	  cell-­‐targeting	  
and	  -­‐penetrating	  agents.	  Finally,	  the	  exceptionally	  small	  diameters	  allow	  these	  
nanoparticles	  to	  penetrate	  relatively	  large,	  clinically	  relevant	  volumes	  when	  
delivered	  by	  CED	  –	  irrespective	  of	  whether	  it	  is	  infused	  through	  tumor-­‐burdened	  
brain	  or	  normal	  parenchyma.	  In	  short,	  this	  is	  a	  delivery	  system	  with	  the	  potential	  
for	  significant	  utility.	  
Although	  the	  highly-­‐penetrative	  polymeric	  nanocarrier	  delivery	  vehicle	  was	  
evaluated	  using	  treatment	  of	  intracranial	  tumors	  with	  small	  molecule	  compounds	  as	  
a	  test	  case,	  the	  system	  could	  easily	  be	  tailored	  for	  application	  to	  a	  host	  of	  central	  
nervous	  system	  disorders.	  For	  example,	  surface	  modification	  or	  size	  fractionation	  
could	  produce	  particles	  well	  suited	  for	  the	  treatment	  of	  neurodegenerative	  
disorders.	  	  Additionally,	  these	  particles	  have	  the	  potential	  to	  encapsulate	  not	  only	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hydrophobic	  drugs	  but	  also	  a	  variety	  of	  nucleic	  acids	  for	  gene	  therapy	  applications	  
[63].	  
	  
Impact	  of	  anti-­‐BCSC	  drugs	  
BCSC	  resistance	  to	  conventional	  chemotherapeutics	  is	  a	  major	  challenge	  toward	  
effective	  GBM	  therapy.	  To	  facilitate	  discovery	  of	  small	  molecule	  drugs	  with	  the	  
ability	  to	  inhibit	  the	  growth	  and	  self-­‐renewal	  of	  BCSCs,	  a	  low-­‐throughput,	  in-­‐house	  
library	  screening	  approach	  was	  first	  used	  successfully.	  Approximately	  2,000	  
compounds	  that	  have	  been,	  at	  one	  time	  or	  another,	  FDA-­‐approved	  were	  tested	  for	  
the	  aforementioned	  abilities.	  32	  lead	  compounds	  were	  identified	  and	  subjected	  to	  
further	  testing.	  We	  originally	  settled	  upon	  the	  anti-­‐helminthic	  cyanine	  dye	  
dithiazanine	  iodide	  for	  its	  abilities	  to	  inhibit	  growth	  and	  self-­‐renewal	  and	  
differentiate	  cells	  it	  fails	  to	  kill.	  Adding	  credibility	  to	  our	  screening	  protocols	  are	  
relatively	  recent	  reports	  confirming	  many	  of	  our	  identified	  drugs	  using	  both	  high-­‐
throughput	  [UCLA]	  and	  small-­‐scale	  approaches	  [80,	  81].	  
Identified	  compounds	  also	  appear	  to	  be	  largely	  generalizable	  based	  on	  preliminary	  
and	  follow-­‐up	  work.	  Our	  in-­‐house	  screen	  identified	  compounds,	  including	  
dithiazanine	  iodide,	  with	  growth	  inhibitory,	  self-­‐renewal-­‐inhibitory,	  and	  pro-­‐
differentiation	  effects	  against	  multiple	  diverse	  BCSC	  lines.	  Based	  on	  prior	  work	  by	  
The	  Cancer	  Genome	  Atlas	  working	  collective,	  each	  cell	  line	  tested	  serves	  as	  a	  proxy	  
for	  a	  different	  subtype	  of	  GBM.	  Our	  early	  results	  suggest	  that	  dithiazanine	  iodide	  is	  a	  
generalizable	  option	  for	  anti-­‐BCSC-­‐directed	  GBM	  therapy.	  Dithiazanine	  iodide	  has	  
anti-­‐growth,	  anti-­‐self-­‐renewal,	  and	  differentiating	  effects	  on	  BCSCs	  –	  but	  the	  extent	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with	  which	  these	  latter	  two	  characteristics	  would	  in	  practice	  have	  an	  effect	  
therapeutically	  remains	  to	  be	  seen.	  The	  remainder	  of	  our	  work	  focuses	  upon	  growth	  
inhibition	  as	  a	  proxy	  for	  in	  vivo	  efficacy.	  
Previous	  work	  in	  humans	  showed	  dithiazanine	  iodide	  to	  have	  significant	  
nephrotoxicity	  when	  delivered	  by	  parenteral	  route,	  and	  subsequent	  work	  identified	  
dithiazanine	  iodide	  as	  being	  significantly	  cytotoxic	  against	  normal	  human	  glial	  cells,	  
raising	  questions	  about	  not	  its	  effectiveness	  but	  its	  safety.	  Granted,	  in	  an	  ethics	  
discussion	  of	  whether	  to	  move	  forward	  with	  a	  compound,	  certain	  costs	  and	  benefits	  
must	  be	  weighed,	  and	  it	  is	  likely	  that	  if	  no	  other	  drug	  worked	  as	  well	  as	  dithiazanine	  
iodide	  and	  were	  simultaneously	  safer,	  we	  would	  of	  course	  move	  forward	  with	  
translation	  of	  dithiazanine	  iodide.	  The	  point,	  however,	  remains	  that	  we	  owe	  it	  to	  
research	  subjects	  –	  and	  future	  patients	  –	  to	  do	  due	  diligence	  to	  the	  best	  of	  our	  
abilities	  in	  the	  search	  for	  the	  most	  efficacious	  and	  safest	  candidate	  drugs.	  
As	  there	  are	  myriad	  compounds	  not	  contained	  within	  our	  set	  that	  may	  have	  anti-­‐
BCSC	  effects,	  it	  was	  important	  to	  increase	  the	  volume	  of	  our	  test	  set.	  Doing	  so,	  
however,	  requires	  new	  methodologies	  in	  order	  to	  be	  both	  cost-­‐effective	  and	  rapid.	  
High-­‐throughput	  screening	  has	  proven	  itself	  as	  a	  rapid,	  accurate,	  and	  precise	  
method	  of	  drug	  discovery.	  
We	  are	  one	  of	  the	  first	  to	  develop	  a	  rapid,	  reproducible,	  and	  accurate	  high-­‐
throughput	  assay	  in	  a	  cancer	  stem	  cell	  line.	  We	  are	  the	  first	  to	  perform	  said	  screen	  
in	  multiple	  diverse	  cancer	  stem	  cell	  lines,	  thus	  showing	  that	  despite	  differences	  in	  
genetic	  programming,	  BCSC	  line	  isolated	  from	  multiple	  distinct	  tumors,	  at	  least	  in	  
terms	  of	  drug	  sensitivity,	  are	  far	  more	  similar	  than	  they	  are	  different.	  This	  insight	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raises	  the	  possibility	  of	  indeed	  finding	  a	  “silver	  bullet”	  treatment	  for	  GBM,	  provided	  
the	  correct	  level	  of	  the	  cellular	  hierarchy,	  rather	  than	  the	  correct	  protein	  or	  gene,	  
can	  be	  targeted.	  
Compounds	  identified	  to	  have	  anti-­‐growth	  efficacy	  against	  all	  BCSC	  lines	  were	  
diverse,	  and	  it	  appears	  unlikely	  from	  initial	  pharmacogenomics	  that	  all	  compounds	  
affect	  a	  final	  common	  pathway.	  Candidate	  drugs	  are	  not	  without	  their	  similarities,	  
however.	  Interestingly,	  seven	  of	  the	  top	  30	  compounds	  with	  anti-­‐BCSC	  efficacy	  and	  
limited	  anti-­‐glial	  cell	  toxicity	  contain	  a	  cationic	  quaternary	  ammonium	  complex.	  
This	  novel	  finding,	  combined	  with	  the	  known	  in	  vivo	  efficacy	  of	  dithiazanine	  iodide,	  
suggest	  that	  quaternary	  ammonium	  compounds	  and	  anti-­‐helminthic	  compounds	  
could	  play	  a	  role	  in	  stunting	  tumor	  propagation.	  Furthermore,	  it	  may	  suggest	  an	  
infectious	  role	  for	  pathogenesis	  and	  propagation	  of	  GBM.	  
The	  role	  of	  safety	  controls	  –	  normally-­‐occurring	  human	  cell	  populations	  –	  in	  high-­‐
throughput	  screens	  has	  been	  discussed	  before.	  Indeed,	  a	  number	  of	  projects	  have	  
either	  relied	  on	  counter	  screens	  or	  on	  direct	  screening	  of	  normal	  populations	  to	  
identify	  novel	  therapeutics	  [70,	  71,	  82-­‐85].	  The	  extent	  to	  which	  in	  vitro	  toxicity	  
mimics	  or	  can	  predict	  in	  vivo	  toxicity	  is	  an	  open	  question.	  Our	  work	  contains	  a	  
normal	  glial	  cell	  control,	  but	  addition	  of	  a	  normal	  mouse	  or	  human	  neural	  stem	  cell	  
line	  as	  well	  as	  a	  neuronal	  line	  would	  serve	  as	  an	  important	  control.	  To	  a	  first	  
approximation,	  we	  can	  perform	  an	  in	  silico	  counter-­‐screen	  by	  comparing	  our	  data	  
with	  the	  data	  of	  the	  Dirks	  laboratory	  at	  the	  University	  of	  Toronto	  [70].	  While	  not	  
comprehensive,	  this	  represents	  an	  important	  first	  step.	  Of	  note,	  zero	  compounds	  are	  
in	  common,	  despite	  the	  libraries	  screened	  in	  both	  sets	  of	  experiments	  being	  quite	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similar.	  Altogether,	  these	  data	  suggest	  that	  our	  candidate	  drug	  compounds	  
identified	  by	  high-­‐throughput	  screening	  are	  accurate,	  efficacious,	  and,	  at	  least	  to	  the	  
level	  with	  which	  we	  can	  approximate	  in	  vivo	  cytotoxicity,	  safe	  for	  use	  in	  humans.	  
Again,	  an	  important	  safety	  control	  is	  the	  fact	  that	  these	  compounds	  at	  one	  time	  or	  
another	  were	  approved	  for	  use	  in	  humans.	  The	  critical	  test	  needed,	  which	  has	  is	  
limited	  by	  time	  and	  money,	  is	  in	  vivo	  evaluation	  of	  each	  candidate	  compound	  in	  
combination	  with	  the	  highly-­‐penetrative	  polymeric	  nanocarrier.	  If	  we	  were	  to	  test	  
each	  promising	  compound,	  the	  number	  of	  rats	  needed,	  including	  appropriate	  free	  
drug	  controls,	  for	  an	  experiment	  with	  reasonable	  power,	  would	  stretch	  into	  the	  
hundreds.	  The	  rigorously	  systematic	  approach	  utilized	  in	  discovering	  these	  
compounds	  merits	  an	  equally	  systematic	  approach	  for	  in	  vivo	  testing.	  At	  present,	  we	  
are	  unable	  to	  do	  this.	  	  
A	  critical	  question,	  which	  could	  be	  adequately	  addressed	  using	  clever	  RNAi-­‐based	  
methodologies	  but	  has	  not	  yet,	  is	  the	  ground	  state	  pathways	  needed	  for	  self-­‐renewal	  
and	  propagation	  of	  BCSCs.	  Pathway	  knowledge,	  in	  addition	  to	  being	  inherently	  
interesting	  and	  possibly	  generalizable	  to	  cancer	  stem	  cells	  in	  other	  diseases,	  may	  
also	  allow	  for	  rational	  design	  of	  drugs	  or	  improvement	  upon	  existing	  candidate	  
compounds.	  To	  this	  end,	  a	  first	  approach	  might	  be	  to	  generate	  RNA	  expression	  array	  
data	  from	  BCSC	  lines	  treated	  with	  various	  candidate	  compounds.	  In	  addition	  to	  
providing	  knowledge	  about	  mechanism	  of	  action	  at	  the	  transcript	  or	  pathway	  level	  
of	  a	  given	  individual	  compound,	  the	  set	  of	  data	  gleaned	  by	  comparing	  transcripts	  or	  
pathways	  from	  different	  BCSC	  lines	  and	  multiple	  candidate	  drugs	  would	  allow	  for	  
the	  definition	  of	  truly	  generalizable	  pathways.	  As	  the	  cost	  of	  collecting	  RNA	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expression	  array	  data	  continues	  to	  decrease,	  this	  will	  one	  day	  be	  possible	  and	  
standard	  practice	  for	  all	  candidate	  compounds.	  
	  
Combined	  Role	  of	  Delivery	  System	  and	  Anti-­‐BCSC	  Drugs	  in	  Treating	  GBM	  
After	  generating	  a	  BCSC-­‐derived	  xenograft	  model	  of	  GBM	  in	  the	  rat	  that	  
recapitulated	  the	  infiltrative	  nature	  of	  the	  native	  disease,	  we	  combined	  the	  results	  
from	  our	  parallel	  drug	  delivery	  and	  drug	  discovery	  investigations	  to	  test	  whether	  
CED	  of	  dithiazanine	  iodide-­‐loaded	  highly-­‐penetrative	  polymeric	  nanocarriers	  could	  
inhibit	  tumor	  growth.	  We	  showed	  that	  the	  combination	  of	  a)	  a	  highly-­‐penetrative	  
polymeric	  nanocarrier-­‐based	  controlled-­‐release	  drug	  delivery	  system	  and	  b)	  a	  novel	  
small	  molecule	  drug	  with	  in	  vitro	  efficacy	  against	  BCSCs	  resulted	  in	  a	  therapeutic	  
that	  had	  an	  unprecedented	  ability	  to	  prolong	  survival	  of	  tumor-­‐bearing	  rats.	  
Altogether,	  this	  suggests	  that	  improved	  treatment	  of	  GBM	  might	  be	  achievable	  if	  
obstacles	  pertaining	  to	  the	  infiltrative	  and	  chemoresistant	  properties	  of	  the	  disease	  
can	  be	  sufficiently	  overcome.	  
	  
Cancer	  Stem	  Cells	  
Based	  on	  the	  data	  presented	  in	  this	  thesis,	  we	  have	  argued	  convincingly	  for	  the	  
combined	  roles	  of	  a	  BCSC-­‐targeting	  drug	  and	  a	  highly-­‐penetrative	  drug	  delivery	  
vehicle.	  The	  latter	  of	  these	  is	  not	  particularly	  surprising:	  Of	  course	  more	  widespread	  
controlled-­‐release	  delivery	  of	  a	  drug	  should	  be	  beneficial.	  What	  was	  made	  clear	  in	  
our	  experiments	  is	  that,	  at	  least	  in	  the	  context	  of	  a	  BCSC-­‐derived	  xenograft	  rat	  
model,	  the	  drug	  contained	  therein	  makes	  a	  huge	  difference.	  The	  previously	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approved	  –	  and	  conventional	  chemotherapeutic	  –	  drug	  paclitaxel	  was	  used	  as	  a	  drug	  
control	  in	  our	  early	  drug	  studies.	  We	  showed	  that	  widespread	  delivery	  of	  this	  
compound	  was	  in	  no	  way	  sufficient	  to	  improve	  survival,	  while	  the	  addition	  of	  
dithiazanine	  iodide	  to	  the	  highly-­‐penetrative	  polymeric	  nanocarrier	  delivery	  vehicle	  
was.	  
GBM	  represents	  a	  special	  case	  in	  oncology	  due	  to	  the	  unique	  delivery	  challenges	  
associated	  with	  its	  location.	  It	  may	  not,	  however,	  be	  particularly	  unique	  in	  terms	  of	  
its	  cellular	  hierarchy	  –	  this	  is	  the	  key	  lesson	  from	  our	  data,	  which	  provide	  more	  
weight	  toward	  the	  cancer	  stem	  cell	  hypothesis	  (insofar	  as	  what	  we	  call	  “cancer	  stem	  
cells”	  and	  what	  we	  isolate	  from	  GBM	  tumors	  using	  our	  state-­‐of-­‐the-­‐art	  methods	  
truly	  are	  the	  stem-­‐like	  subpopulation	  of	  cells	  from	  a	  tumor	  responsible	  for	  the	  
development	  of	  vasculature,	  proliferation	  of	  the	  tumor,	  and	  the	  significant	  invasion	  
throughout	  the	  brain	  parenchyma.	  
While	  intertumoral	  genetic	  heterogeneity	  has	  become	  a	  very	  hot	  topic	  in	  the	  world	  
of	  drug	  discover	  and	  drug	  development	  (as,	  essentially,	  the	  basis	  of	  personalized	  
drug	  therapy),	  the	  extent	  to	  which	  intratumoral	  genetic	  heterogeneity	  must	  be	  
addressed	  in	  drug	  discover	  and	  development	  remains	  to	  be	  seen.	  Fortunately,	  high-­‐
throughput	  small	  molecule	  screening	  has	  made	  possible	  the	  rapid	  evaluation	  of	  anti-­‐
proliferation	  effects	  of	  small	  molecule	  compounds.	  While	  not	  accounted	  for	  in	  this	  
study,	  answering	  the	  question	  can	  be	  addressed	  simply	  with	  scaling.	  
An	  open	  question,	  of	  course,	  is	  the	  extent	  to	  which	  the	  BCSCs	  cultured	  	  
Recent	  mouse	  model	  evidence	  has	  added	  further	  force	  to	  the	  cancer	  stem	  cell	  
hypothesis	  within	  GBM	  [86].	  In	  studies	  of	  BCSCs,	  however,	  isolation	  of	  the	  cell	  lines	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and	  subsequent	  in	  vivo	  modeling	  –	  and	  high-­‐throughput	  small	  molecule	  screening	  –	  
relies	  on	  culture	  of	  these	  cells	  in	  serum-­‐free	  media.	  The	  effects	  culturing	  these	  cells	  
have	  has	  not	  been	  quantified,	  but	  is	  likely	  to	  be	  significant.	  One	  possible	  future	  
experiment	  to	  account	  for	  this	  effect	  is	  laser	  capture	  microdissection	  of	  the	  
perivascular	  niche	  of	  these	  germ	  line-­‐derived	  GBMs	  in	  mice.	  Genetic	  studies	  –	  from	  
expression	  arrays,	  to	  sequencing,	  to	  methylation	  studies	  –	  and	  small	  molecule	  
sensitivity	  studies	  would	  be	  possible,	  and	  neural	  stem	  cell	  controls	  in	  the	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Figures	  &	  Legends	  
	  
Figure	  1.	  Method	  of	  fabrication	  of	  highly-­‐penetrative	  polymeric	  nanocarriers.	  
PLGA	  =	  poly(lactic-­‐co-­‐glycolic)	  acid;	  PVA	  =	  polyvinyl	  alcohol.	  Adapted	  from	  Zhou	  et	  
















	   	   	   	   	   	   	   	   	   	  




Figure	  2.	  (A)	  Primary	  screening	  testing	  effects	  of	  ~3,000	  compounds	  on	  three	  
different	  BCSC	  lines.	  Top	  compounds	  were	  re-­‐screened	  in	  BCSC	  lines	  and	  safety	  
screened	  in	  normal	  glial	  cells	  SVGp12.	  (B)	  Basic	  schematic	  of	  screening	  protocol.	  
	  
Figure'2'
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Figure	  3.	  Preliminary	  low-­‐throughput	  in-­‐house	  small	  molecule	  screen	  for	  anti-­‐
brain	  cancer	  stem	  cell	  compounds.	  Screening	  strategy	  with	  number	  of	  hits	  from	  
each	  stage	  (A).	  Summary	  of	  cytotoxicity,	  self-­‐renewal	  inhibition,	  and	  differentiation	  
results	  of	  candidate	  compound	  dithiazanine	  iodide	  in	  three	  independently	  isolated	  
brain	  cancer	  stem	  cell	  lines.	  Adapted	  from	  Zhou	  et	  al,	  2013,	  Proceedings	  of	  the	  
National	  Academy	  of	  Sciences	  [21].	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Figure	  4.	  In	  vivo	  assessment	  of	  dithiazanine	  iodide-­‐loaded	  ultrasmall	  
nanoparticles	  in	  rats	  bearing	  brain	  cancer	  stem	  cell-­‐derived	  xenograft	  tumors.	  
Kaplan-­‐Meier	  survival	  curve	  for	  dithiazanine	  iodide-­‐loaded	  ultrasmall	  NPs	  (blue),	  
dithiazanine	  iodide-­‐loaded	  standard	  NPs	  (red),	  free	  dithiazanine	  iodide	  in	  solution	  
(green),	  unloaded	  ultrasmall	  NPs	  (yellow),	  and	  no	  treatment	  (gray).	  Adapted	  from	  
Zhou	  et	  al,	  2013,	  Proceedings	  of	  the	  National	  Academy	  of	  Sciences	  [21].	  
	  
Figure'4'
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Figure	  5.	  High-­‐throughput	  small	  molecule	  screen	  quality	  control.	  2D	  scatter	  
plots	  of	  relative	  fluorescence	  intensity	  signals	  from	  two	  independent	  experiments	  in	  
(A)	  GS5,	  (B)	  PS16,	  (C)	  PS30,	  and	  (D)	  SVGp12.	  (E)	  Plot	  of	  Z’	  values	  from	  primary	  





	   	   	   	   	   	   	   	   	   	  




Figure	  6.	  High-­‐throughput	  small	  molecule	  screen	  quality	  control,	  summary	  of	  
systematic	  plate	  effects.	  (A)	  Schematic	  of	  data,	  differentially	  colored	  wells	  refer	  to	  
a	  given	  well.	  (B)	  Figure	  showing	  the	  luminosity	  of	  each	  row	  in	  a	  given	  column	  from	  a	  






Figure 6: Systematic row effects. (a) Each of the displays corresponds to one of the 22 columns in
the plate (ordered from 2 to 23, from left to right, top to bottom). Within each display, the intensity
values for all wells in a given column across all plates are plotted against their row number. (b)
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Figure	  7.	  Primary	  high-­‐throughput	  small	  molecule	  screening	  in	  brain	  cancer	  
stem	  cell	  lines.	  (A)	  3D	  scatter	  plot	  of	  relative	  efficacy	  results	  in	  GS5	  (x),	  PS16	  (y),	  
and	  PS30	  (z)	  cell	  lines.	  (B)	  Venn	  diagram	  showing	  overlap	  of	  cell	  line	  sensitivities	  to	  
any	  drug	  with	  >	  50%	  inhibition.	  (C)	  3D	  scatter	  plot	  of	  relative	  efficacy	  results.	  
Compounds	  chosen	  for	  secondary	  screening	  are	  in	  red.	  
Figure'7'
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Figure	  8.	  Counter-­‐screening	  of	  candidate	  small	  molecule	  compounds	  against	  
SVGp12	  normal	  human	  glial	  cell	  line.	  (A)	  Percent	  of	  SVGp12	  cells	  killed	  by	  
candidate	  drug	  compound	  dithiazanine	  iodide	  at	  escalating	  doses,	  compared	  with	  
temozolomide	  and	  DMSO	  vehicle	  controls.	  (B)	  Scatter	  plot	  of	  anti-­‐glial	  cell	  toxicity	  
versus	  mean	  anti-­‐brain	  cancer	  stem	  cell	  anti-­‐growth	  activity.	  Compounds	  in	  red,	  as	  
most	  active	  against	  brain	  cancer	  stem	  cells,	  were	  highest-­‐rated	  candidate	  
compounds.	  (C)	  Compounds	  from	  (B)	  in	  red	  displayed	  as	  bar	  graph	  ordered	  by	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Figure	  9.	  T1	  MR	  imaging	  of	  superparamagnetic	  iron	  oxide-­‐loaded	  highly-­‐
penetrative	  polymeric	  nanocarriers.	  High-­‐volume	  infusate	  at	  time	  0	  (A-­‐B)	  and	  
time	  28	  days	  (C-­‐D).	  Hyperdensities	  present	  in	  both	  A	  and	  C	  indicate	  position	  of	  
nanoparticles.	  B	  and	  D	  are	  anatomically	  corresponding	  density	  maps	  of	  A	  and	  C.	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scans.	  “Bubbles”	  of	  volume	  associated	  with	  infusate	  and	  displaced	  brain	  tissue	  but	  
not	  nanoparticles	  can	  be	  seen	  as	  black	  space	  (larger	  in	  E	  for	  high-­‐volume	  and	  
smaller	  in	  F	  for	  low-­‐volume).	  T1	  images	  for	  low-­‐volume	  infusate	  at	  time	  of	  infusion	  
(G)	  and	  one	  month	  (I),	  with	  hyperdensity	  again	  indicating	  nanoparticles.	  
Anatomically	  corresponding	  density	  maps	  can	  be	  seen	  in	  H	  and	  J;	  owing	  to	  slight	  
inter-­‐procedural	  positional	  variation,	  saturation	  can	  be	  seen.	  Images	  between	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Tables	  &	  Legends	  
	  
Table	  1.	  World	  Health	  Organization	  Histologic	  Grading	  Criteria	  of	  Gliomas.	  Red	  
text	  denotes	  gliomas	  of	  oligodendrocyte	  lineage	  while	  blue	  text	  denotes	  gliomas	  of	  
astrocytic	  lineage.	  Microscopy	  findings	  typically	  noted	  on	  simple	  H&E	  staining.	  Ki67	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Table	  2.	  Compounds	  identified	  in	  in-­‐house	  screening	  for	  anti-­‐BCSC	  effects.	  
Small	  molecules	  with	  greater	  than	  50%	  neurosphere	  inhibition	  and	  with	  greater	  
than	  50%	  proliferation	  inhibition.	  Identified	  compounds	  were	  compared	  to	  “finalist”	  
compounds	  from	  Visnyei	  et	  al,	  Molecular	  Cancer	  Therapeutics,	  2011.	  Only	  three	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Table	  3.	  In	  vitro	  efficacy	  characterization	  of	  candidate	  compounds	  identified	  
in	  in-­‐house	  screen.	  Percent	  inhibition	  values	  as	  calculated	  for	  digoxin,	  acriflavine,	  
and	  emetine	  in	  five	  different	  cell	  lines	  under	  normoxic	  conditions	  and	  in	  the	  GS5	  line	  
under	  hypoxic	  conditions	  (90%	  O2,	  5%	  CO2,	  and	  5%	  N2).	  Notably,	  digoxin	  has	  only	  
minimal	  anti-­‐growth	  effects	  against	  bulk	  tumor	  cells,	  suggesting	  that	  if	  it	  is	  to	  be	  
used	  as	  a	  therapeutic,	  it	  should	  be	  combined	  with	  a	  known	  inhibitor	  of	  bulk	  tumor	  
cell	  growth	  such	  as	  BCNU,	  PCV,	  or	  temzolomide.	  
	  
	  
Table	  4.	  In	  vitro	  efficacy	  characterization	  of	  candidate	  compounds	  identified	  
in	  in-­‐house	  screen.	  Percent	  inhibition	  values	  as	  calculated	  for	  digoxin,	  acriflavine,	  
and	  emetine	  in	  five	  different	  cell	  lines	  under	  normoxic	  conditions	  and	  in	  the	  GS5	  line	  
under	  hypoxic	  conditions	  (90%	  O2,	  5%	  CO2,	  and	  5%	  N2).	  
	  
Drug GS5 PS16 PS24 PS30 U87 GS5 (Hypoxia) 
Digoxin 40.1 ± 13.9% 70.5 ± 2.7% 30.6 ± 5.6% 14.0 ± 5.4% 0 ± 0.9% 84.4 ± 2.3% 
Acriflavine 92.9 ± 0.8% 85.3 ± 3.1% 94.5 ± 1.7% 83.1 ± 5.0% 95.5 ± 0.2% 82.8 ± 0.9% 
Emetine 98.3 ± 0.3% 93.9 ± 4.8% 99.3 ± 1.4% 84.4 ± 1.7% 95.2 ± 0.3% 88.2 ± 0.7% 
Drug GS5 PS16 PS24 PS30 U87 GS5 (Hypoxia) 
Digoxin 472 nM 38 nM 69 nM 82 nM -- 19 nM 
Acriflavine 2.44 µM 1.29 µM 774 nM 1.50 µM 949 nM 502 nM 
Emetine 134 nM 50 nM 51 nM 58 nM 14 nM 73 nM 
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Table	  5.	  Compounds	  with	  in	  vitro	  mean	  anti-­‐BCSC	  efficacy	  greater	  than	  
anisomycin.	  Compounds	  are	  ordered	  by	  mean	  efficacy,	  where	  efficacy	  is	  a	  number	  
from	  0	  to	  1,	  with	  1	  reflecting	  100%	  killing	  of	  cells	  at	  8uM	  dose	  and	  0	  reflection	  0%	  
killing	  of	  cells	  at	  the	  same	  dose.	  Notable	  is	  the	  number	  of	  compounds	  with	  efficacy	  
reaching	  >90%,	  a	  number	  previously	  reached	  only	  by	  dithiazanine	  iodide,	  the	  only	  
small	  molecule	  compound	  we	  have	  shown	  efficacious	  in	  an	  in	  vivo	  model	  of	  GBM.	  
Compound(ID( Mean(BCSC(Efficacy( SEM(
YU034074' 0.9176' ±' 0.0228'
YU225107' 0.9169' ±' 0.0236'
YU226758' 0.9136' ±' 0.0235'
YU226560' 0.9132' ±' 0.0241'
YU227095' 0.9126' ±' 0.0232'
YU221339' 0.9118' ±' 0.0224'
YU033988' 0.9114' ±' 0.0244'
YU227090' 0.9112' ±' 0.0235'
YU226768' 0.9109' ±' 0.0226'
YU226510' 0.9100' ±' 0.0234'
YU226487' 0.9099' ±' 0.0223'
YU226751' 0.9072' ±' 0.0219'
YU224245' 0.9041' ±' 0.0234'
YU034420' 0.9018' ±' 0.0237'
YU224111' 0.9003' ±' 0.0205'
YU225125' 0.8972' ±' 0.0209'
YU221332' 0.8821' ±' 0.0309'
YU221036' 0.8787' ±' 0.0232'
YU226578' 0.8694' ±' 0.0423'
YU227152' 0.8627' ±' 0.0692'
YU226647' 0.8619' ±' 0.0276'
YU227021' 0.8409' ±' 0.0406'
YU154826' 0.8385' ±' 0.0250'
YU226471' 0.8339' ±' 0.0314'
YU227292' 0.8328' ±' 0.0386'
YU226739' 0.8286' ±' 0.0568'
YU225124' 0.8253' ±' 0.0445'
YU227165' 0.8245' ±' 0.0362'
YU221952' 0.8232' ±' 0.0471'
YU225073' 0.8126' ±' 0.0583'
YU224088' 0.8113' ±' 0.0469'
YU226361' 0.7825' ±' 0.0556'
YU040321' 0.7786' ±' 0.0539'
YU225086' 0.7746' ±' 0.1440'
YU226894' 0.7631' ±' 0.0491'
YU030802' 0.7561' ±' 0.0560'
YU225136' 0.7553' ±' 0.0462'
YU039604' 0.7440' ±' 0.0453'
YU039847' 0.7437' ±' 0.1268'
YU225128' 0.7435' ±' 0.0538'
YU221336' 0.7415' ±' 0.0840'
YU034048' 0.7346' ±' 0.0783'
YU226392' 0.7345' ±' 0.0570'
YU226869' 0.7255' ±' 0.0529'
YU039629' 0.7213' ±' 0.0609'
YU226852' 0.7130' ±' 0.0666'
YU039788' 0.7127' ±' 0.0651'
YU155446' 0.7123' ±' 0.0582'
YU154853' 0.7044' ±' 0.0354'
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